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ABSTRACT 
!
Uterine carcinosarcoma (CS), leiomyosarcoma (LMS) and endometrial stromal sarcoma 
(ESS), which have historically been considered as subtypes of uterine sarcomas (USs), 
represent only a small proportion of uterine malignancies. However, it has been estimated that 
USs account for nearly one third of deaths from uterine malignancies (Nordal and Thoresen 
1997).  
The aims of these studies were to assess clinical behavior, survival, prognostic markers and 
epidemiological aspects of uterine CS, LMS and ESS. In a retrospective study we analyzed 
survival and prognostic markers (both clinical and immunohistochemical) in patients treated 
from 1990 to 2001 at Helsinki University Central Hospital (HUCH). In the epidemiological 
studies the incidence and occupational risk of uterine LMS and ESS were examined by using 
the NORDCAN and Nordic Occupational Cancer Study (NOCCA) databases. A cohort of 
8606 cases of USs from 13 cancer registries was used to evaluate the risk of a second primary 
malignancy after the first primary US. This study was coordinated by the International 
Agency for Research on Cancer (IARC). 
The age-adjusted incidence of LMS was about 0.4–0.5 per 100 000 and that of ESS about 0.2 
per 100 000 in Iceland, Denmark, Finland and Norway during the study period 1978–2007. 
Age-specific incidences were highest around menopause for both subtypes of USs. Shoe and 
leather workers, farmers and teachers showed elevated standardized incidence ratios (SIRs) as 
regards LMS. However, no occupations were associated with increased SIRs in connection 
with ESS.  
One hundred patients with uterine CS (n = 40), LMS (n = 39) and ESS (n = 21) were treated 
in our institution during 1990–2001. The 2-, 5-, and 10-year disease-specific survival rates 
were 64%, 56% and 38% for all subtypes grouped together and 5-year survival rates for each 
subtype separately were 49% (CS), 57% (LMS) and 65% (ESS). Stage, age, tumor size and 
delivery status were independently associated with survival when all subtypes were 
combined. Immunohistochemical (IHC) analysis (n = 65) of ten markers showed that estrogen 
receptor-α (ER-α) and progesterone receptor (PR) positivity were associated with statistically 
significantly better disease-specific survival times and p53 positivity with worse disease-
specific survival in patients with LMS. 
The risk of a second primary cancer after the first primary US was analyzed in a cohort of 
8606 cases of USs, in which 499 cancer cases were observed. Women with a primary US had 
a 26% increased risk (SIR 1.26, 95%CI 1.16–1.38) of developing a second primary cancer. 
SIRs were elevated as regards cancers of the mouth and pharynx (2.16, 95%CI 1.15–3.69), 
colorectum (1.60, 95%CI 1.28–1.98), lung (1.73, 95%CI 1.27–2.29), breast (1.25, 95%CI 
1.05–1.49), urinary bladder (1.74, 95%CI 1.02–2.79), kidney (2.00, 95%CI 1.24–3.06), 
thyroid gland (2.74, 95%CI 1.42–4.79), and soft tissue sarcoma (5.23, 95%CI 2.51–9.62). The 
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risk of breast cancer increased along with increasing age at US diagnosis (p trend=0.040). The 
risk of kidney cancer increased along with lower age at the time of US diagnosis (p trend = 
0.004) and short time since US diagnosis (p trend = 0.018). 
 
In conclusion, the incidences of LMS and ESS showed constant trends in Nordic countries 
during the study period. Overpresentation of uterine LMS in shoe and leather workers and 
farmers might be associated with the etiology of LMS and this should be clarified in the 
future. Our institutional survival rates in cases of uterine CS, LMS and ESS were comparable 
with or even better than in earlier reports, and stage, age, tumor size, and delivery status of the 
patient emerged as the main prognosticators. Immunohistochemical expression of ER-α, PR 
and p53 were associated with survival of patients with LMS. After diagnosis of US there is an 
elevated risk of a second primary malignancy. Excesses of colorectal and urinary bladder 
cancers may reflect the effects of earlier treatments of US (radiotherapy and chemotherapy). 
The elevated risk of mouth and pharynx, lung and urinary bladder cancers after USs might be 
associated with common etiological factors such as smoking. The excesses of breast cancer in 
US patients may be related to a shared hormonal etiology.  
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INTRODUCTION 
 
In 2010, 29197 incident cancers and 11677 cancer deaths were registered in Finland. 
According to the Finnish Cancer Registry, 14402 cancers and 1592 cancers of female 
reproductive organs were diagnosed in women during the same year (www.cancer.fi). More 
than 130000 incident cancers and nearly 60000 cancer deaths are observed in the Nordic 
countries every year (Engholm et al. 2010a). The number of new cancer cases has tripled in 
Finland during the last fifty years but the number of cancer deaths has stayed stable for many 
years (Pukkala et al. 2011).   
Depending on the classification, 3% to 9% of malignancies of the uterine corpus and about 
1% of all female genital tract malignancies are uterine sarcomas (USs, Nordal and Thoresen 
1997, McMeekin 2007). The trend in incidence of malignancies of the uterine corpus has been 
increasing in Finland: 709 of these malignancies were registered per year from 1999!to!2003 
and 804 in 2010. This category also includes USs in the Finnish Cancer Registry statistics 
(ICD-10 numbers C54.21, C54.22, C54.23 and C54.29). However, the exact number of USs is 
not shown in the statistics of the Finnish Cancer Registry (www.cancer.fi), but the estimated 
number of new USs is about 20 to 25 per year in Finland.   
Knowledge of the etiology, risk factors and incidence of USs and second primary 
malignancies after USs is scanty, and no studies on occupational risks of USs exist. No 
consensus of treatment methods for USs in adjuvant or recurrent settings has been reached. In 
addition, survival figures as regards USs have been unchanged for several years, and no new 
prognosticators have emerged. In the present studies we focused on uterine carcinosarcoma 
(CS), leiomysarcoma (LMS) and endometrial stromal sarcoma (ESS), and our aim was to 
clarify epidemiological, clinical and prognostic aspects of these malignancies. 
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REVIEW OF THE LITERATURE 
 
CLASSIFICATION OF UTERINE SARCOMAS 
!
Uterine sarcomas are a heterogeneous group of malignancies. Historically, USs have been 
classified as carcinosarcomas (CSs, about 40% of cases), leiomyosarcomas (LMSs, 40%) and 
endometrial stromal sarcomas (ESSs, 15%) (McMeekin 2007). The remaining 5% consist of a 
heterogeneous group of vascular, lymphatic and heterologic sarcomas. Recent studies have 
revealed increasing evidence that CS is a subtype of endometrial carcinoma (McCluggage 
2002a, McCluggage 2002c). The updated classification is as follows: LMS (60%), ESS 
(30%), undifferentiated endometrial sarcoma (UES, =undifferentiated uterine sarcoma, 5%) 
and adenosarcoma (5%) (Amant et al. 2009a). Nevertheless, CS is still included in many 
studies and reviews of US. The recent and historical classification of USs is summarized in 
Table 1. 
 
Table 1. Classification of uterine sarcomas 
 
Historical Classification of Uterine Sarcomas Recent Classification of Uterine Sarcomas 
Carcinosarcoma (40%) - 
Leiomyosarcoma (40%) Leiomyosarcoma (60%) 
Endometrial Stromal Sarcoma (15%) 
-low-grade 
-high-grade 
 
Low-grade Endometrial Stromal Sarcoma (30%) 
Undifferentiated Endometrial Sarcoma (5%) 
Other uterine sarcomas (5%) Adenosarcoma and other uterine sarcomas (5%) 
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EPIDEMIOLOGICAL ASPECTS 
!
Incidence of uterine sarcomas 
!
Uterine sarcomas represent up to 9% of uterine cancers (Nordal and Thoresen 1997, 
McMeekin 2007). In Finland, the age-adjusted incidence rate of US in 20032007 was 0.7 per 
100 000 (NORDCAN database (Engholm et al. 2010a,b)). In Norway, the annual incidence 
rate of USs was as high as 1.7 per 100 000 females in 19871992 (Nordal and Thoresen 1997) 
and the incidence rate was the same in 19731981 in the United States (Harlow et al. 1986). 
 
Risk factors of uterine sarcomas 
 
Age and ethnic background 
The sparse amount of data on the age-specific incidences of US has shown the peak 
incidences of LMS ranging from 4549 (Harlow et al. 1986) to 5064 years (Nordal and 
Thoresen 1997) and a peak incidence of ESS in the age group 5064 years (Nordal and 
Thoresen 1997). The incidence of CS has been noticed to increase after menopause (Harlow 
et al. 1986, Nordal and Thoresen 1997).  
Variation in US incidence has been reported among different races (Harlow et al. 1986, Platz 
and Benda 1995). The age-adjusted incidence among blacks has been twice that of whites and 
more than twice that of women of other races (Brooks et al. 2004). 
 
Parity and obesity 
Uterine sarcoma is a very rare malignancy in pregnant woman. However, the majority (38%) 
of 40 genital sarcomas reported during pregnancy over a period of 50 years of time, were USs 
according to a recently published review (Matsuo et al. 2009). 
The incidence of US has been described as being higher among women never-married than 
women ever-married and it has been explained by nulliparity among never-married women 
(Schwartz and Weiss 1990). However, the association between parity and the risk of US is 
unclear: both lower risk (Kvale et al. 1988, Albrektsen et al. 1995) and no association have 
been described  (Schwartz et al. 1991). 
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Obesity is a potential risk factor of US (Schwartz et al. 1996). Schwartz and co-workers 
reported elevated risks of CS, LMS and ESS among patients with a body mass index over 
27kg/m2. 
 
Smoking, hormonal treatment and radiation therapy 
In only one study has smoking been investigated in connection with USs. Smoking was 
associated with lower risks of LMS (n = 56) and ESS (n = 26) but no association was found 
with CS (n = 85). The odds ratio was 0.6 (95% CI 0.3–1.1) for LMS and 0.5 (95%CI 0.1–1.2) 
for patients with ESS among women who had ever smoked cigarettes  (Schwartz et al. 1996). 
Long-term use of hormonal agents, both for contraception and replacement therapy, has been 
associated with a raised risk of US (Schwartz et al. 1996, Jaakkola et al. 2011). Women, who 
had used estradiol-progestin therapy for more than 5 years, had a 2.6-fold increased risk of 
LMS (Jaakkola et al. 2011). Tamoxifen treatment has also been linked to an elevated risk of 
US (Wickerham et al. 2002, Arenas et al. 2006). 
An elevated risk of USs, especially CS, has been detected after pelvic radiation for malignant 
disease (Meredith et al. 1986). 
 
Occupational risks of gynecological cancers 
!
Cancer risks according to occupational affiliation reflect possible occupational carcinogenic 
exposure as well as lifestyle habits, cultural norms and the socioeconomic positions of certain 
occupational groups. The results of occupational cancer studies will help in the development 
of preventive actions and may give clues to etiological factors of different cancers. The 
limitations of these kinds of epidemiological studies can include the absence of data on 
confounding factors and lack of power to detect associations. It has been estimated that about 
5% of all cancer cases in Finland may have been related to work in the time-period of 1971–
1985 (Pukkala 1995). 
Several studies of occupational risks and exposures in connection with gynecologic cancers 
have been published (Shen et al. 1998, Vasama-Neuvonen et al. 1999, Weiderpass et al. 2001, 
Shields et al. 2002, Pukkala et al. 2009, Riska et al. 2012). Weiderpass et al. found no 
occupational categories with a statistically significantly elevated relative risk of endometrial 
cancer, but for cervical cancer increased risks were detected among woodworkers, road and 
streetcar service personnel, painters, restaurant waitresses, textile inspectors, plywood and 
fiberboard workers and bar and cafeteria waitresses. When they linked cancer risks with job-
exposure matrices (JEMs), endometrial cancer was associated with exposure to animal-related 
dust and sedentary work, and cervical cancer was associated with exposure to aliphatic, 
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alicyclic, aromatic and chlorinated hydrocarbon solvents, silica and wood dust (Weiderpass et 
al. 2001). In 2009 Pukkala et al. published the results of a study on a large Nordic cancer 
incidence cohort analyzed by occupational category. Artistic workers and dentists had the 
highest risks of endometrial cancer and female beverage worker and drivers presented the 
lowest risks in their report. On the other hand they noticed significantly increased cervical 
cancer rates among beverage workers, “other construction workers”, waiters, tobacco 
manufacture workers, drivers and electrical workers and significantly decreased cervical 
cancer rates among dentists, physicians, teachers, farmers and nurses (Pukkala et al. 2009). 
Elevated ovarian cancer rates have been associated with occupations such as dry cleaning, 
telegraph and telephone work, paper packaging, graphic and printing work. Hairdressers and 
beauticians have also been reported to have an increased risk of ovarian cancer, but this 
finding is inconsistent. Organic dusts, aromatic amines, aliphatic and aromatic hydrocarbons 
have been suggested as specific etiologic agents for ovarian cancer in the JEM analyses (Shen 
et al. 1998, Vasama-Neuvonen et al. 1999, Shields et al. 2002). Riska et al. recently published 
a study of occupational risks in connection with primary fallopian tube carcinoma: 
significantly increased risks were observed among smelting workers, artistic workers, 
hairdressers, packers, nurses, shop workers and clerical workers. They also reported 
significantly low risks among women working in farming and among economically inactive 
women (Riska et al. 2012). 
 
Second primary cancers after first primary gynecological cancer 
!
In recent decades, cancer has become transformed from being a fatal disease to a disease that 
can be treated with very effective methods, and patients can either be cured or live for a 
longer time with cancer. This long-term survivorship has made the risk of second primary 
cancers more obvious. The raised incidence of second primary cancer after any malignancy 
could be a result of intensive surveillance after the first cancer diagnosis, the effects of 
different treatment modalities (chemo- and radiotherapy), and/or shared etiological, 
environmental and genetic factors between the first and second malignancy (Boice et al. 
1985b). About 16% of new incident cancers reported in the SEER data were second- or higher 
order primary cancers in 2003 (Travis 2006). 
The probability of developing an independent second primary malignancy after radiotherapy 
increases with time, and such malignancies are observed in the lining cells of the body and in 
tissues and organs that have received radiation (Hall and Wuu 2003). Typical second primary 
malignancies that can be induced by radiotherapy are solid tumors such as breast, thyroid, 
lung, stomach, colon, esophagus, bladder, ovary, brain and liver cancers (Travis 2006). 
Chemotherapy can be another risk factor as regards an increased incidence of second primary 
malignancies and the risk begins to increase from one to two years after treatment (Travis 
2006, Grosse et al. 2009). A few chemotherapeutic agents have been linked to solid tumours: 
 16 
 
cyclophosphamide to bladder cancer, mechlorethamine (+ nitrogen mustard), vincristine, 
procarbazine and prednisone combined chemotherapy to lung cancer and alkylating agents to 
bone sarcomas (Hawkins et al. 1996, Travis 2002, Grosse et al. 2009). Both chemo- and 
radiotherapy can cause leukemia, but occurrence after the use of cytotoxic drugs is more 
common.  
Several studies concerning second malignancies after first primary female genital tract cancer 
have been published (Boice et al. 1985a, Curtis et al. 1985, Storm and Ewertz 1985, Bergfeldt 
et al. 1995, Kaldor et al. 1995, Travis et al. 1999, Weinberg et al. 1999, Hemminki et al. 2003, 
Ohno et al. 2006, Riska et al. 2007a, Srinivasan et al. 2007, Chaturvedi et al. 2009, Brown et 
al. 2010). Significantly increased risks have been reported as regards cancers of the breast, 
colon, esophagus, kidney, lung, oral cavity, ovaries, pharynx, rectum, urinary bladder, vagina, 
and vulva, and leukemias. Patients with ovarian cancer seem to have the greatest risk of 
developing a second primary malignancy (Curtis et al. 1985, Storm and Ewertz 1985, 
Bergfeldt et al. 1995). Genetic, environmental (infections, smoking, hormonal aspects), and 
treatment-related (chemo- and radiotherapy) factors and strict surveillance are thought to 
explain the increased risks after first primary gynecologic cancer. 
In various studies significantly increased risks of a second primary malignancy at any site 
after endometrial cancer have been noticed (Curtis et al. 1985, Storm and Ewertz 1985, 
Bergfeldt et al. 1995, Hemminki et al. 2003, Brown et al. 2010). Curtis et al. (1985) reported a 
risk ratio (RR) of 1.30 (95%CI 1.22–1.38), Bergfeldt et al. (1995) and Hemminki et al. (2003) 
standardized incidence ratios (SIRs) of 1.21 (95%CI 1.12–1.30) to 1.54 (95%CI 1.48–1.61) 
for all second cancers. In the two other studies, SIRs were 0.99 (95%CI 0.99–1.14) and 1.04 
(95%CI 0.96–1.01) (Storm and Ewertz 1985, Brown et al. 2010). In all studies significant 
excesses of colon cancers were noticed after first primary endometrial cancer. Other common 
sites with excesses of cancers have been the breast and urinary bladder. In a recent study, 
significantly decreased rates of second primary cancers have been detected at certain sites 
such as the oral cavity, pharynx and lung (Brown et al. 2010). The pattern of second 
neoplasms after endometrial cancer may be associated with genetic factors (HNPCC), 
treatment effects (colon, urinary bladder), shared etiological factors and intensive clinical 
surveillance. 
In a study including more than 25,000 primary female genital tract cancers, second primary 
cancers were analyzed in a subgroup of 905 women with USs: a nonsignificantly increased 
risk (RR 1.30, 95%CI 0.96–1.72) as regards all sites combined was observed (Curtis et al. 
1985).  
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CLINICAL FEATURES 
 
Symptoms, signs and diagnosis 
!
The clinical presentation of US is nonspecific. The most common symptom of US, regardless 
of the type, is abnormal vaginal pre- or postmenopausal bleeding (Giuntoli et al. 2003, Benoit 
et al. 2005, McMeekin 2007, Wu et al. 2011). The patient may have an enlarged uterus, a 
palpable abdominal mass, abdominal pain, or only a poor general condition, especially in 
cases with advanced-stage of the disease (Sagae et al. 2004, Benoit et al. 2005). Sometimes 
CS can cause a polypoid mass protruding from the cervix, which is noticed in a gynecological 
examination (McMeekin 2007, Wu et al. 2011). Patients with USs rarely have no symptoms 
at all (Benoit et al. 2005).  
Preoperative diagnosis is demanding and problematic depending on the US subtype (Amant et 
al. 2009a). Correct preoperative diagnosis of malignancy has been reported in 93.5% of CSs, 
35% of LMSs and 25% of ESSs and as regards preoperative sarcoma diagnosis in 24%, 23% 
and 20% of cases, respectively (Sagae et al. 2004). The reported incidence of US among 
patients operated upon for a benign leiomyoma or a rapidly growing leiomyoma has been 
only 0.23% (Parker et al. 1994). 
Women with bleeding disorders and suspected malignancy are examined by way of 
endometrial biopsy or curettage. In cases of CS, endometrial biopsy samples frequently 
include only the epithelial component of the malignancy (McMeekin 2007). The difficulty of 
diagnosing LMS and ESS preoperatively by endometrial biopsies may be related to the 
mesechymal origin of the tumors. By means of endometrial cytology 52% of CSs, 15% of 
LMSs and 5% of ESSs have been reported to be correctly diagnosed (Sagae et al. 2004). 
Endometrial preoperative sampling (biopsy or curettage) has led to correct identification of 
malignancy in 86% (28/32 CS, 3/4 LMS and 2/2 ESS) and correct histologic diagnosis in 64% 
of the US cases. The detection rate in cases of invasive cancer was nearly equal among USs 
and endometrial carcinomas, but preoperative sampling was less reliable in predicting the 
correct histology of USs compared with epithelial tumors (Bansal et al. 2008). Cervical 
cytology (Pap smear) is of no benefit in the detection of US (Wang et al. 2002). 
Imaging methods, such as ultrasonography, color Doppler ultrasonography, computerized 
tomography (CT) and magnetic resonance imaging (MRI), may help in diagnosing US. 
However, none of these can lead to precise preoperative diagnosis (Cacciatore et al. 1989, 
Sahdev et al. 2001, Amant et al. 2009a, Brocker et al. 2011, Wu et al. 2011). Even with MRI, 
the differentiation of LMS from a benign leiomyoma is demanding: a high signal intensity in 
T2-weighted images of large infiltrating myometrial masses is associated with LMS (Brocker 
et al. 2011, Wu et al. 2011). ESSs can be seen as invasive endometrial masses in MRI images 
(Sahdev et al. 2001) and they infiltrate either sharply or diffusely into the myometrium 
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(Koyama et al. 1999). MRI findings in CS are similar to those in endometrial adenocarcinoma 
and are indistinguishable in 88% of cases (Bharwani et al. 2010). 
F-fluorodeoxyglucose positron emission tomography (FDG-PET) with computerized 
tomography (FDG-PET-CT), which combines both metabolic and anatomical findings in the 
evaluation of tumors (Rigo et al. 1996), might be useful in connection with metastatic or 
recurrent USs  (Wu et al. 2011). In a small case series, use of FDG-PET allowed detection of 
all US cases, compared with detection rates 80% with MRI and 40% with power Doppler 
imaging (Umesaki et al. 2001). FDG-PET-CT has been reported to be highly sensitive and 
specific as regards detecting US recurrence during surveillance (Park et al. 2008a, Sharma et 
al. 2011), although no significant benefit over CT, MRI or ultrasonography was observed 
(Sharma et al. 2011). 
Preoperative assay of the serum tumor marker CA125 is of limited value. In one study, 40% 
of cases of USs were reported to show elevated levels of CA125 before treatment (Duk et al. 
1994). However, all sarcoma cells were negative in CA125 immunohistochemistry (IHC), and 
positivity was seen only in the epithelial component of CS (Duk et al. 1994). Raised CA125 
levels have been associated with extrauterine disease and deep myometrial invasion in CS 
patients (Huang et al. 2007). Uterine leiomyomas can be associated with elevated levels of 
CA125 and this should be taken into account in the diagnostics of uterine LMS (He et al. 
2011, Moore et al. 2012). 
 
Histopathology 
!
Carcinosarcoma is composed of both malignant epithelial and mesenchymal cells. The 
epithelial element is frequently endometrioid or serous and rarely clear cell, mucinous or 
squamous. The sarcomatous elements may be either homologous (tissues from the Műllerian 
tract such as endometrial stroma, fibrous tissue or smooth muscle) or heterologous (foreign 
tissues such as skeletal muscle, cartilage, bone or adipose tissue) (Tavassoli and Devilee 
2003, D'Angelo and Prat 2011). Carcinosarcoma is still classified as a mixed epithelial and 
mesenchymal tumor (2003 WHO diagnostic criteria), although based on clinical and 
molecular evidence, CS is a poorly differentiated metaplastic carcinoma (McCluggage 
2002c). The biphasic tumor components have an influence on the immunoprofile of CS and 
IHC expression of cytokeratins, epithelial membrane antigen, p53, desmin, myogenin, 
MyoD1, vimentin and even CD10 can be seen (D'Angelo and Prat 2010). By definition, CS is 
always a high-grade tumor. 
Leiomyosarcoma is a malignant, hypercellular neoplasm composed of spindle cells from the 
smooth muscle compartment of the uterus. The tumor presents cellular atypia, tumor cell 
necrosis and a high mitotic index, which means over 15 mitotic figures per 10 high-power 
fields (HPFs). In addition to ordinary LMS, rare tumor variants such as epithelioid and 
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myxoid LMS exist (Tavassoli and Devilee 2003, D'Angelo and Prat 2010). The differential 
diagnosis of LMS from benign smooth muscle tumors and smooth muscle tumors of uncertain 
malignant potential (STUMP) has become easier since application of the 2003 WHO 
diagnostic criteria. For LMS, no grading system has been universally accepted (Tavassoli and 
Devilee 2003, Abeler et al. 2009). 
In IHC of LMS, the expression of smooth muscle markers such as actin, desmin, h-
caldesmon, and histone deacetylase is detected. Epithelioid LMS can express epithelial 
markers such as keratin and epithelial membrane antigen. The mesenchymal tumor marker 
vimentin is almost always positive in LMSs (McCluggage 2002b, D'Angelo and Prat 2010, 
Abeler and Nenodovic 2011). The expression of estrogen receptors (ERs), progesterone 
receptors (PRs) and androgen receptors (ARs) in LMS has varied from 0 to 100% (Bodner et 
al. 2003, Kitaoka et al. 2004, Leitao et al. 2004, Akhan et al. 2005, D'Angelo et al. 2009, Ioffe 
et al. 2009, Leitao et al. 2012). The ratio of ER-α /ER-β expression in LMSs was shown to be 
0.06 in a recent study (Rodriguez et al. 2011), but usually only the expression of ER-α has 
been analyzed and reported. PR also exists as two isoforms, A and B. However, many 
commercial antibodies react with both isoforms, and investigators have not reported them 
separately. Expression of the proliferation marker Ki-67, p16 and p53 proteins, and various 
isoforms of the hyaluronate receptor CD44 can distinguish LMS from benign leiomyomas 
(Poncelet et al. 2001, Chen and Yang 2008). More than 50% of LMSs can react positively for 
CD10, a common acute lymphoblastic leukemia antigen (McCluggage et al. 2001, D'Angelo 
and Prat 2010, Abeler and Nenodovic 2011).  
Endometrial stromal sarcoma is derived from the endometrial stromal cells, which are oval to 
spindle-shaped and infiltrate the myometrium. Small arterioles, foamy cytoplasmic cells, 
endometrial-type glands and even sex cord-like structures may be detected. Focal smooth 
muscle differentiation is less than 30%. The mitotic activity of ESS is usually low. ESS is a 
low-grade tumor by definition and high-grade endometrial stromal sarcoma is nowadays 
classified as undifferentiated endometrial sarcoma (UES) (Tavassoli and Devilee 2003). ESS 
is immunoreactive as regards CD10, vimentin, actin, keratin, ER and PR (Reich et al. 2000, 
Chu et al. 2001, D'Angelo and Prat 2010). Most ESSs have been reported to express ER-α, 
and both isoforms of PR. PRA has been the predominant isoform in one study (Balleine et al. 
2004). 
Adenosarcoma is a biphasic tumor, which consists of a benign epithelial component and a 
sarcomatous mesenchymal component. The epithelial component may show focal metaplastic 
changes. The mesenchymal part of adenosarcoma is usually a low-grade homologous stromal 
sarcoma with varying amounts of fibrous tissue and smooth muscle. Typically, mitotic figures 
are low in the mesenchymal component, and cytological atypia is mild. Adenosarcoma is 
immunoreactive as regards different cytokeratins, focally for CD10 and in varying degrees for 
smooth muscle markers (Tavassoli and Devilee 2003). Adenosarcomas lacking sarcomatous 
overgrowth also express ER and PR (Amant et al. 2004). 
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A undifferentiated endometrial sarcoma is a high-grade sarcoma without smooth muscle or 
endometrial stromal differentiation. This neoplasm shows marked cellular atypia, and high 
mitotic activity, and it resembles the sarcomatous component of CS. The aggressive growth 
pattern of UES typically displaces the myometrium. UESs are immunoreactive as regards Ki-
67, p53 and p16 and usually no immunoreactivity is seen as regards ERs and PRs (Tavassoli 
and Devilee 2003, D'Angelo et al. 2009). 
Altogether, a broad panel of ICH markers seems to be useful when analyzing uterine 
mesenchymal tumors (Zhu et al. 2004, Abeler and Nenodovic 2011). 
 
Staging 
!
USs are staged surgically and staging was defined by means of modified FIGO criteria for 
carcinomas of the endometrium until 2009 (Table 2, (International Federation of Gynecology 
and Obstetrics 2006)). In 2009 FIGO updated the staging system and introduced a new system 
for each type of US, except for CS, which is staged as carcinoma of the endometrium (Tables 
3–5, (Mutch 2009)). 
 
Table 2. FIGO staging system (1988) for carcinoma of the endometrium 
 
Stage  Definition 
Stage I   
 Ia Tumor limited to endometrium, no myometrial invasion 
 Ib Less than half of myometrial invasion 
 Ic More than or equal to myometrial invasion 
Stage II   
 IIa Endocervical glandular involvement only 
 IIb Cervical stromal invasion  
Stage III   
 IIIa Tumor invades serosa and/or adnexa and/or positive peritoneal cytology 
 IIIb Vaginal metastases 
 IIIc Metastasis to pelvic and/or para-aortic lymph nodes 
Stage IV   
 IVa Tumor invades bladder or bowel mucosa 
 IVb Distant metastasis 
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Table 3. FIGO staging system (2009) for LMS and ESS 
 
Stage   Definition 
Stage I  Tumor limited to uterus 
 IA Less than or equal to 5cm 
 IB More than 5 cm 
Stage II II Tumor extends beyond the uterus, within the pelvis 
 IIA Adnexal involvement 
 IIB Involvement of other pelvic tissue 
Stage III  Tumor invades abdominal tissues (not just protruding into the abdomen) 
 IIIA One site 
 IIIB More than one site 
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
Stage IV   
 IVA Tumor invades bladder and/or rectum 
 IVB Distant metastasis 
 
Table 4. FIGO staging system (2009) for adenosarcoma 
 
Stage  Definition 
Stage I  Tumor limited to uterus 
 IA Tumor limited to endometrium/endocervix with no myometrial invasion 
 IB Less than or equal to half myometrial invasion 
 IC More than half myometrial invasion 
Stage II  Tumor extends beyond the uterus, within the pelvis 
 IIA Adnexal involvement 
 IIB Involvement of other pelvic tissue 
Stage III  Tumor invades abdominal tissues (not just protruding into the abdomen) 
 IIIA One site 
 IIIB More than one site 
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
Stage IV   
 IVA Tumor invades bladder and/or rectum 
 IVB Distant metastasis 
 
Table 5. FIGO staging system (2009) for carcinoma of the endometrium 
 
Stage  Definition 
Stage I  Tumor limited to uterus, no involvement of uterine serosa 
 IA Less than or equal to half myometrial invasion 
 IB More than half of myometrial invasion 
Stage II  Tumor invades cervical stroma but does not extend beyond the uterus 
Stage III  Tumor involves the uterine serosa, adnexae, vagina, or retroperitoneal lymph nodes 
 IIIA Involvement of uterine serosa, and/or the adnexae 
 IIIB Vaginal involvement 
 IIIC Involvement of retroperitoneal lymph nodes 
 IIIC1 Positive pelvic nodes 
 IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph nodes  
Stage IV  Tumor involves rectal or bladder mucosa and/or distant organs 
 IVA Tumor invades mucosa of the rectum or bladder 
 IVB Distant metastasis 
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Treatment 
 
Surgery 
The treatment of USs has been based on surgery for years. The surgical gold standard has 
been extrafascial hysterectomy, with or without bilateral salpingo-oophorectomy (BSO) and 
pelvic lymph node dissection (LND). The diversity of histologic subtypes and different 
clinical behavior has influenced surgical recommendations.  
The surgical treatment of CS comprises hysterectomy with BSO, systematic pelvic 
lymphadenectomy with or without para-aortic lymphadenectomy and comprehensive 
peritoneal staging (peritoneal cytology, omentectomy and peritoneal biopsies) (Gadducci et 
al. 2008, McMeekin 2007). Extended surgery is indicated by a reported high rate of lymph 
node (14-38%) (Callister et al. 2004, Nemani et al. 2008, Galaal et al. 2009) and adnexal 
metastases (22%) (Callister et al. 2004). Lymphadenectomy has been associated with 
improved survival, and in early-stage disease, the lymph node count has also correlated with 
the risk of recurrence and with survival (Temkin et al. 2007, Nemani et al. 2008). The 
survival of advanced-stage patients with CS (stages IIIC–IVB) has been shown to be better 
when no macroscopic residual tumor is left after cytoreductive operation (Tanner et al. 2011). 
For LMS, which is mainly spread via the bloodstream rather than the lymphatic system, and 
ESS, the value of LND is low and the surgical treatment recommendation is simple 
hysterectomy (Gadducci et al. 2008, McMeekin 2007, Amant et al. 2009a, Nam 2011). 
Lymph node metastases are observed in about 11% of LMS cases (Giuntoli et al. 2003, Leitao 
et al. 2003, Kapp et al. 2008), but in earlier series the rates have been much higher, from 26% 
to 75% (Chen 1989, Goff et al. 1993, Gadducci et al. 1996). In cases of ESS, the most 
common incidence of lymph node metastasis has been less than 10% (Goff et al. 1993, Chan 
et al. 2008, Shah et al. 2008), although higher rates of up to 33% have also been reported 
(Riopel et al. 2005). Both with LMS and ESS patients, LND should be carried out as a 
cytoreductive procedure if the disease is extrauterine or if bulky lymph nodes are found 
during primary surgery (Gadducci et al. 2008, Amant et al. 2009a, Nam 2011). 
A debate concerning oophorectomy among LMS patients has been ongoing for a long time. 
The reported incidence of ovarian metastasis has been only 4% (Leitao et al. 2003). 
Nowadays BSO is recommended for postmenopausal women with LMS. For premenopausal 
women, preservation of macroscopically normal ovaries is possible (Gadducci et al. 2008, 
Amant et al. 2009a, Nam 2011), since the risk of recurrence has not been found to increase 
with ovarian preservation (Gadducci et al. 1996, Giuntoli et al. 2003). In one study, the 
survival of young LMS patients (matched by age, grade and stage) was the same among cases 
with and without oophorectomy (Giuntoli et al. 2003).  
Oophorectomy is recommended for ESS patients, because most ESSs are hormone-sensitive 
diseases (McMeekin 2007). Beck et al. reported that the recurrence rate was lower among 
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ESS patients who underwent BSO in primary operation (Beck et al. 2012). However, in recent 
studies the survival of premenopausal women with early-stage ESS with and without 
oophorectomy has been shown to be the same (Amant et al. 2007, Shah et al. 2008, Chan et 
al. 2008), and therefore individualization of the surgical approach is recommended in this 
group of patients (Amant et al. 2009a, Nam and Park 2010). In addition, the incidence of 
adnexal metastasis has been 13% and it usually occurs with macroscopically abnormal 
adnexes and extrauterine disease (Dos Santos et al. 2011).  
Management of menopausal symptoms with estrogens is not recommended for ESS patients 
because of the high rate hormone-sensitivity of this tumor type (Chu et al. 2003, Pink et al. 
2006, Amant et al. 2009a). The same recommendation and individual caution could be 
applied among patients who have hormone receptor-positive LMS, although the literature on 
this matter is scanty (Burger et al 1999, Ursic-Vrscaj 1999). 
The surgical procedures are summarized in Table 6. 
 
Table 6. Surgical procedures in cases of uterine carcinosarcoma (CS), leiomyosarcoma (LMS) 
and endometrial stromal sarcoma (ESS) 
 
 Hysterectomy BSO LND Omentectomy Peritoneal cytology/biopsies  
CS + + +* + +/+ 
LMS + ± - - +/- 
ESS + + - - +/- 
BSO = bilateral salpingo-oophorectomy, LND = lymph node dissection, *pelvic and para-aortic 
 
Adjuvant therapies 
Only a few prospective controlled trials of adjuvant therapies for USs have been carried out. 
When grouping all subtypes, neither radiotherapy nor chemotherapy has improved survival in 
adjuvant settings (Sagae et al. 2004, Benoit et al. 2005, Hensley 2011, Sampath and Gaffney 
2011). However, radiotherapy may reduce the risk of local recurrence (Chauveinc et al. 1999, 
Gadducci et al. 2007, Sampath and Gaffney 2011). 
 
Chemotherapy 
Chemotherapy is a standard treatment both for completely resected and metastatic CS 
(Gadducci et al. 2008, Hensley 2011) because there is an extremely high risk of recurrence. 
About 50% of early-stage diseases and about 90% of advanced-stage diseases will recur 
(McMeekin 2007). For CS, active cytotoxic drugs are carboplatin, cisplatin, ifosfamide and 
paclitaxel (Gadducci et al. 2008, Homesley et al. 2007, Wolfson et al. 2007, Makker et al. 
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2008, Powell et al. 2010, Hensley 2011). Combinations of ifosfamide and carboplatin, or 
carboplatin and paclitaxel have been demonstrated to be the most beneficial regimens in first-
line therapy, both in early- and advanced-stage CS (Hensley 2011). In stage III/IV, persistent, 
or recurrent CS the response rates in connection of these combination therapies have ranged 
from 45 to 62% (Homesley et al. 2007, Powell et al. 2010, Lacour et al. 2011). 
The suggested standard procedure in cases of totally resected, uterus-limited LMS is 
observation (Amant et al. 2009a, Hensley 2011). However, the estimated risk of recurrence is 
more than 50% in patients with LMS, even in early-stage disease (Dinh et al. 2004), and 
therefore adjuvant chemotherapy is also used among patients who have completely resected, 
high-grade LMS. Traditionally, chemotherapy has been recommended in advanced-stage, 
inoperable or recurrent LMS, in which case the treatment is usually non-curative (Kanjeekal 
et al. 2005, Amant et al. 2009a). For years, patients with LMS have been subjected to various 
doxorubicin-based regimens in first-line treatment because of the documented efficacy of 
doxorubicin in connection with LMS (Omura et al. 1983, Omura et al. 1985, Sutton et al. 
1996a, Pautier et al. 2004). Response rates have been 20–30% in cases of advanced or 
recurrent LMS (Omura et al. 1983, Muss et al. 1985, Omura et al. 1985, Sutton et al. 1996a). 
Better response rates (27% to 53%) were achieved in three prospective phase II trials with 
fixed-dose rate gemcitabine and docetaxel in the treatment of unresectable or metastatic LMS, 
after which this regimen was accepted as a first-line regimen in metastatic and relapsed 
disease (Hensley et al. 2002, Hensley et al. 2008a, Hensley et al. 2008b). In 2009, Hensley et 
al. published the results of a prospective study of women with completely resected stage I–IV 
LMS treated with four cycles of fixed-dose rate gemcitabine plus docetaxel: 45% of all 
treated patients remained disease-free at 2 years (Hensley et al. 2009a). In the SARC005 
study, women with completely resected stage I–III, high-grade LMS received four cycles of 
fixed-dose rate gemcitabine plus docetaxel, followed by four cycles of doxorubicin: 78% of 
the patients remained progression-free at 2 years (Hensley et al. 2010).  
Trabectedin has proven activity among patients with locally advanced or metastatic LMS, and 
this new regimen may be a therapeutic option after first- or second-line treatment failures with 
gemcitabine and docetaxel, and doxorubicin-based regimens (Amant et al. 2009b, Ray-
Coquard 2011, Sanfilippo et al. 2011). In a recent phase II study, the activity of trabectedin 
was assessed in the first-line treatment of advanced, persistent and recurrent uterine LMS: 
only 10% of the patients had a partial response, 50% had stabilized disease, and the median 
progression-free survival period was 5.8 months (Monk et al. 2012).  
For completely resected ESS, no adjuvant chemotherapy is normally recommended 
(Gadducci et al. 2007, Amant et al. 2009a, Hensley 2011). Advanced stage or hormone-
unresponsive diseases should be treated with active cytotoxic agents, such as ifosfamide and 
doxorubicin (Sutton et al. 1996b). 
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Radiotherapy 
Recommendations concerning adjuvant radiotherapy in the treatment of USs vary and are 
mainly based on the results of retrospective studies (Sampath and Gaffney 2011). Only two 
randomized-controlled phase III studies have been published (Wolfson et al. 2007, Reed et al. 
2008). For early-stage CS, improved local control is the strongest evidence for adjuvant 
pelvic radiotherapy (Sampath and Gaffney 2011). Adjuvant radiotherapy for LMS and ESS 
patients is thought to be non-beneficial (Reed et al. 2008, Amant et al. 2009a, Barney et al. 
2009), but with both subtypes there is tendency to show improved local control compared 
with patients treated by means of surgery alone (Figure 1: modified from that by Sampath and 
Gaffney (2011)). 
Figure 1. Local failure rate (%) as regards different types of uterine sarcomas after using 
adjuvant radiotherapy (RT) or no adjuvant radiotherapy 
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Endocrine therapy 
Older data showed that hormone therapy (medroxyprogesterone acetate, tamoxifen, or both) 
was ineffective among US patients (Wade et al. 1990). For a long time, ESS was thought to 
be the only subtype of US that responds to hormonal manipulation (Garrett and Quinn 2008). 
However, both ESS and LMS express ERs, PRs and ARs to different degrees, but hormone 
receptor expression of CS is almost always negative (D'Angelo et al. 2009, D'Angelo and Prat 
2010).  
The suggested mechanisms of different hormone therapies are as follows: progestins exert an 
anti-estrogenic effect through binding to the PRs, aromatase inhibitors (AIs) block the 
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conversion of androgens to estrogens in peripheral-fat tissue and the antiprogestin 
mifepristone, which is a selective PR modulator, acts via competitive interaction with 
progesterone at PR sites, or it can produce a progesterone-like effect in the absence of 
progesterone (Ramondetta et al. 2009, Bouchard et al. 2011). The anti-cancer activity of 
mifepristone is also likely to be multifactorial and mifepristone has been shown to inhibit the 
growth of different cancer cell lines even without the necessity of nuclear PR (Tieszen et al. 
2011). The anti-estrogen tamoxifen is nowadays associated with an increased risk of US, 
which might be caused by its estrogenic activity in endometrial stroma and glands 
(Wickerham et al. 2002, Chu et al. 2003, Arenas et al. 2006). 
For patients with CS, hormone therapy is usually useless, because these tumors are mostly 
hormone receptor-negative. However, in a few cases of recurrent or advanced CS progestin 
therapy has brought about stabilization of the disease, lasting from 3 to 34 months (Ioffe et al. 
2009).  
Many case reports and studies on series have been published as regards hormone therapy for 
LMS and ESS, especially with progestins (medroxyprogesterone and megestrol) and AIs 
(letrozole and anastrazole), both in adjuvant settings and in cases of recurrent or advanced 
disease (Uchida et al. 1996, Maluf et al. 2001, Leunen et al. 2004, Pink et al. 2006, Hardman 
et al. 2007, Ioffe et al. 2009, O'Cearbhaill et al. 2010). For ESS patients, 76% of cases have 
reported to respond to progestins and nearly 88% to AIs (Amant et al. 2009a). Low-grade 
ESS has also reported to express aromatase in IHC analysis (Reich and Regauer 2004). 
Patients with recurrent LMS have shown partial clinical responses to progestin or AI therapy 
in case reports (Uchida et al. 1996, Hardman et al. 2007). In two retrospective studies, 40% to 
100% of patients with recurrent or advanced LMS treated with AIs responded to therapy 
(stable disease or partial response) (Ioffe et al. 2009, O'Cearbhaill et al. 2010). In a recent 
review it was concluded that AIs seem to have an effective role in the treatment of ESS and 
might help to stabilize LMS progression (Altman et al. 2012). Phase II studies of letrozole in 
the treatment of LMS (adjuvant and recurrent settings) are ongoing in the United States 
(http://clinicaltrials.gov).  
Two case reports of patients with recurrent ESS treated with a gonadotropin-releasing 
hormone analog alone or with progestin have been published (Burke and Hickey 2004, 
Dupont and Disaia 2010). In these reports, a partial response and a complete response were 
achieved, respectively. In a small phase II trial, twelve patients with advanced or recurrent 
endometrioid adenocarcinoma (n = 10) or low-grade ESS (n = 2) were treated with 
mifepristone. The treatment resulted in stable disease in 25% of all patients and one of the 
two ESS patients (Ramondetta et al. 2009). 
Nowadays hormone therapy is accepted as one type of targeted treatment, with benefit in 
hormone receptor-positive uterine LMS and ESS (Amant et al. 2009a, Sjoquist et al. 2011, 
Altman et al. 2012). Good patient compliance is achieved with these therapies because all 
hormone therapies have been well tolerated with no appreciable side effects (Ioffe et al. 2009, 
Ramondetta et al. 2009, O'Cearbhaill et al. 2010, Altman et a. 2012).  
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Targeted treatment 
Several biomolecular treatment options have been studied, mainly in phase II trials, in cases 
of USs or soft-tissue sarcomas (Amant et al. 2009a, Hensley 2011). Different tyrosine kinase 
inhibitors, such as imatinib, sunitinib, sorafenib and pazopanib have been assessed in cases of 
recurrent or persistent USs and STSs: response rates have been less than 10% (Hensley et al. 
2009b, Maki et al. 2009, Sleijfer et al. 2009, Huh et al. 2010). Bevacizumab, which is a 
monoclonal antibody that inhibits vascular endothelial growth factor A, has been added to 
doxorubicin (D'Adamo et al. 2005) or gemcitabine and docetaxel treatment in phase I/II trials 
in cases of advanced soft tissue sarcomas (Verschraengen et al. 2008). D´Adamo et al. 
reported partial responses in two patients (2/7, 28%) with uterine LMS and Verschraengen et 
al. in two patients who had no site-specified LMS (2/5, 40%). In both studies the 
combinations showed activity in advanced soft tissue sarcomas even thought the cardiac 
toxicity of doxorubicin and adverse events associated with bevacizumab warrant further 
studies. A phase III study of gemcitabine and docetaxel with or without bevacizumab in the 
treatment of patients with advanced or recurrent uterine LMS is ongoing in the United States 
(http://clinicaltrials.gov). 
In future, possible targets for therapy of US could be Wilms tumor gene 1 (WT1) and 
cyclooxygenase-2 (COX-2, tumor growth and metastasis promoting enzyme) (Amant et al. 
2009a). COX-2 has been found to be overexpressed in uterine LMS and WT1 in uterine CS, 
LMS, ESS and UES (Coosemans et al. 2007, Tesfaye et al. 2007). WT1 might be an attractive 
target for immunotherapy of USs, and COX-2 inhibitors (sulindac, celecoxib) could be used 
in COX-2-positive LMSs (Amant et al. 2009a). 
 
Recurrent disease 
!
More than 50% of patients with primary CS and LMS who have completely responded will 
relapse (Dinh et al. 2004, McMeekin 2007, Abeler et al. 2009). Even though ESS is a low-
grade disease, recurrences may develop in as many as a third to a half of patients over a long 
period of time (Chang et al. 1990). Typical sites for recurrences of USs are the pelvis, liver 
and lungs (McMeekin 2007). 
Surgery, radiotherapy, chemotherapy, hormone therapy or a combination of these treatments 
is an option for relapsed US. For LMS and ESS, all treatment modalities are possible, and 
surgery (sometimes repeatedly) is the best choice if a single metastasis, for example in the 
liver or lungs, is diagnosed (Amant et al. 2009a). Recurrence of CS is mainly treated by 
means of chemotherapy, as is the case in most multiple site recurrences of LMS and ESS. The 
same cytotoxic drugs as in adjuvant treatment are utilized, and 0–57% of all cases of recurrent 
US have been reported to respond to various forms of chemotherapy (Kanjeekal et al. 2005). 
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Before starting hormone therapy, receptor status should be determined (Amant et al. 2009a). 
Radiotherapy is a possible choice for palliative, symptom-relieving treatment in all cases of 
recurrent US. 
The treatment options for uterine CS, LMS and ESS are summarized in Figures 2–4. The 
Figures are modified from Amant, IGCS 2010, Prague, and Amant et al. (2009a). 
 
 
 
Figure 2. Clinical management of uterine carcinosarcoma 
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Figure 3. Clinical management of uterine leiomyosarcoma (LMS) 
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Figure 4. Clinical management of endometrial stromal sarcoma (ESS) 
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Survival  
The best 5-year survival rates are found among patients with ESS and the worst among 
patients with CS and LMS. Overall 5-year survival in all cases of uterine sarcoma has varied 
from 17% to 59% in different reports (Table 7). Five-year survival rates in cases of CS, LMS 
and ESS are summarized in Tables 8–10. 
Table 7. Type distribution and 5-year survival (%) in cases of uterine sarcoma 
 
Study n 
 
 
CS 
n (%) 
LMS 
n (%)  
ESS 
n (%) 
Other  
sarco- 
mas  
n (%) 
Study  
period 
5-year 
overall 
survival  
 
Nieminen et al. 1974 117 9 (8) 71 (61) 17 (14) 20 (17) 1937–1964 54.7 
Kahanpää et al. 1986 119 45 (38) 51 (43) 23 (19) 0 (0) 1958–1977 42 
Olah et al. 1992 423 152 (36) 215 (51) 26 (6) 30 (7) 1967–1981 31 
Nordal and Thoresen 
1997 
1042 284 (27) 476 (46) 124 (12) 158 (15) 1971–1975 
1983–1987 
50.2#  
48# 
Chauveinc et al. 1999 73 23 (32) 32 (44) 14 (19) 4 (5) 1975–1995 45 
Pautier et al. 2000 157 52 (33) 78 (59) 27 (17) 0 (0) 1976–1995 40 
el Husseiny et al. 2002 59 20 (34) 25 (42) 14 (24) 0 (0) 1980–1997 48* 
Gadducci et al. 2002 249 101(41) 95 (38) 53(21) 0 (0) 1980–1994 41.6 
Brooks et al. 2004 2677 NR NR NR NR 1989–1999 42–53# 
Livi et al. 2005 40 12 (30) 24 (60) 3 (8) 1 (2) 1980–2001 25** 
Benoit et al. 2005 72 25 (35) 34 (47) 12 (17) 1 (1) 1966–2001 36.1 
Kokawa et al. 2006 97 46 (47) 36 (37) 15 (16) 0 (0) 1990–2003 17.5 
Denschlag et al. 2007 94 36 (56) 30 (32) 28 (30) 0 (0) 1989–2004 47 
Park et al. 2008 127 44 (35) 46 (36) 37 (29) 0 (0) 1987–2007 59 
Abeler et al.2009 419 - 259 (62) 85(20) 75(18) 1970–2000 NR 
Albrektsen et al. 2009b 493 118 (24) 249 (51) 126 (26) 0 (0) 1960–1999 NR 
CS = carcinosarcoma, LMS = leiomyosarcoma, ESS = endometrial stromal sarcoma, NR = not reported, # 
relative, *Estimate from the figure published by el Husseiny et al., **5-year disease-specific survival % 
 
Table 8. Five-year survival (%) by stage in cases of uterine carcinosarcoma 
 
Study n Stage I Stage II Stage III Stage 
IV 
All  
stages 
Nordal et al. 1997 46 40 25 15 0 31 
Blom et al. 1998b 44 53.5 (stage I-II)* - 20 (stage III-IV)* - 38 
Sagae et al 2004 46 78.8 80 41.6 0 NR 
Callister et al 2004 300 37 21 27 - 31 
Galaal et al. 2009 93 46 (stage I-II) - 10 (stage III-IV)* - 33 
Gonzalez Bosquet  
et al. 2010 
121 59 (stage I-II) - 22 9 NR 
Nieminen et al. 1974 9     33.3 
Kahanpää et al. 1986 45     33 
Nordal and Thoresen 
1997 
284     36.8–44 
Chauveinc et al. 1999 23     35 
Pautier et al. 2000 52     37 
Benoit et al. 2005 25     34.8 
Kokawa et al. 2006 46     16.7 
Denschlag et al. 2007 36     23 
Nemani et al. 2008 1855     49#–34## 
Albrektsen et al. 2009b 118     55 
NR = not reported,  #/##Lymph node dissection done/not done, *Estimate from the figure published by Blom et 
al., Galaal et al. 
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Table 9. Five-year survival (%) by stage in cases of uterine leiomyosarcoma 
 
Study n Stage I Stage II Stage III Stage IV All stages 
Giuntoli et al.2003 208 62* 45* 35* 20* NR 
Sagae et al. 2004 40 73 100 0 0 NR 
Wu et al. 2006 51 73* - 43* (Stage III-IV) - 67.4  
Kapp et al. 2008 1396 75.8 60.1 44.9 28.7 65.7 
Nieminen et al. 1974 71     66.2 
Kahanpää et al. 1986 51      39 
Gadducci et al. 1996 126     40** 
Nordal and Thoresen 1997 476      45.9–50.4 
Chauveinc et al. 1999 32     33 
Mayerhofer et al. 1999 71     65 
Pautier et al. 2000 78      35 
Benoit et al. 2005 34      30.2 
Kokawa et al. 2006 36     16 
Denschlag et al. 2007 30     40 
Abeler et al. 2009 235     43# 
Albrektsen et al. 2009b 249     68 
NR = not reported, *Estimate from the figure published by Giuntoli et al., Wu et al., **5-year disease-free 
survival %, estimate from the figure published by Gadducci et al., #Estimate from the figure published by Abeler 
et al. 
 
Table 10. Five-year survival in cases of endometrial stromal sarcoma 
 
Study n All stages 
Nieminen et al. 1974 17 52.9 
Kahanpää et al. 1986 23 61 
Nordal et al. 1996 48 69 
Nordal and Thoresen 1997 124 73–83.7 
Chauveinc et al. 1999 14  84 
Pautier et al. 2000 27  57 
Bodner et al. 2001 31 62 
Sagae et al. 2004 20 94.7* 
Benoit et al. 2005 12 58.5 
Kokawa et al. 2006 15 25 
Denschlag et al. 2007 28 82 
Chan et al 2008 831 76.2 
Abeler et al. 2009 85 76** 
Albrektsen et al. 2009b 126 74 
*Stage I, **Estimate from the figure published by Abeler et al. 
 
!
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PROGNOSTIC FACTORS 
!
Age  
!
Advancing age of patients with CS, LMS and ESS has been related to an unfavorable clinical 
outcome, both in univariate and multivariate analysis in almost all studies (Chan et al. 2008, 
Kapp et al. 2008, Nemani et al. 2008, Gadducci 2011). It has been reported that women with 
LMS aged over 50 had an 11.07-fold and women with ESS aged over 55 had a 6.47-fold 
increased risk of death (Wu et al. 2006, Garg et al. 2010).  
 
Ethnic background 
!
In recent SEER studies, black race has been an independent, negative predictor of survival 
among patients with CS, LMS and ESS (Chan et al. 2008, Kapp et al. 2008, Nemani et al. 
2008). In earlier SEER data, white women with stage I US of all subtypes showed better 5-
year relative survival than African-American women, but this difference was diminished 
when adjusting for adjuvant treatment of US (Brooks et al. 2004). Brooks and co-authors 
concluded that the poorer survival could be associated with a lower rate of referral to health 
care or less frequent use of adjuvant therapies (Brooks et al. 2004). 
 
Parity 
!
Studies in which parity has been evaluated as a prognostic factor of US are sparse. Nulliparity 
has been found to adversely affect the survival of patients with CS in one study (Marth et al. 
1997). Sagae et al. reported an opposite finding among patients with CS (Sagae et al. 2004). 
In two other studies, parity has had no effect on the survival of patients with CS (Nordal et al. 
1997, Bodner-Adler et al. 2001). In a recent study of 126 patients with ESS, 249 patients with 
LMS and 118 patients with CS, nulliparity was associated independently with poorer survival 
only among ESS patients (p = 0.058) (Albrektsen et al. 2009b). 
 
Grade  
!
Carcinosarcoma is by definition a high-grade tumor and ESS a low-grade tumor, and with 
these subtypes grade should not be assessed as a prognostic variable (Tavassoli and Devilee 
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2003). Historically, patients with high-grade ESS, nowadays classified as UES, have had 
poorer outcome than those with low-grade ESS (Nordal et al. 1996). In most studies, high-
grade LMS has been associated with worse prognosis (Olah et al. 1992, Giuntoli et al. 2003, 
Kapp et al. 2008), but studies showing no association have also been published (Nordal et al. 
1995, Wu et al. 2006).  
 
Histology 
!
The prognostic value of the histological subtype of US has been established in only a few 
studies (Nordal and Thoresen 1997, Gadducci et al. 2002). In a Norwegian study, the survival 
of patients with ESS was better than that of patients with LMS and CS (p < 0.001) (Nordal 
and Thoresen 1997). In an Italian study, the risk of death was significantly lower among 
patients with low-grade ESS (RR 0.257 95%CI 0.071–0.931) and CS (RR 0.509, 95%CI 
0.324–0.799) compared with patients with LMS (Gadducci et al. 2002).  
 
Immunohistochemistry 
!
Several immunohistochemical markers have been studied as prognostic factors of USs 
(Gadducci 2011). Many investigators have looked at the prognostic clinical significance of 
the hormone receptors ER, PR and AR (Leitao et al. 2004, Akhan et al. 2005, Huang et al. 
2007, Huang et al. 2009, Ioffe et al. 2009, Leitao et al. 2012). ER-α expression has been 
associated with a reduced risk of death and ER-β expression with a negative predictive value 
among CS patients (Huang et al. 2007, Huang et al. 2009). ER- and PR-positivity have been 
associated with better survival among LMS patients (Leitao et al. 2004, Akhan et al. 2005, 
Leitao et al. 2012), and ER expression has been associated with improved overall survival in 
all cases of US (Ioffe et al. 2009). 
Overexpression of the mutant protein p53 has been demonstrated to be a prognostic factor as 
regards uterine LMS (Blom et al. 1998a, Anderson et al. 2006, Kim et al. 2006, D'Angelo et 
al. 2009). However, Nordal et al. found no impact of p53 accumulation on prognosis of US 
(all subtypes combined) and similar results have been published among patients with CS and 
ESS (Blom et al. 1998b, Iwasa et al. 1998, Nordal et al. 1998, Blom et al. 1999). Low Ki-67 
expression has been linked to better survival of LMS patients and longer recurrence-free 
survival of ESS patients (Popiolek et al. 2003, Mayerhofer et al. 2004, Akhan et al. 2005, 
D'Angelo et al. 2009). Overexpression of the mutant protein p16 has been associated with a 
negative effect on the survival of LMS patients, and the oncogene Twist, which inhibits 
apoptosis, might be associated with worse survival of LMS patients (p = 0.07) (D'Angelo et 
al. 2009). 
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In recent studies COX-2, WT1 and Bcl-2 (apoptosis marker) have been evaluated in cases of 
US. COX-2 was observed to be an independent negative prognostic marker as regards LMS 
(Lee et al. 2011) and WT1 as regards LMS, CS and UES (Coosemans et al. 2011). Positive 
immunostaining of Bcl-2 protein in LMSs was associated with a longer time to recurrence and 
a longer period of overall disease-specific survival (Leiser et al. 2006, D'Angelo et al. 2009) 
and this marker could be used in combination with tumor size, mitotic index and Ki-67 
expression (D'Angelo et al. 2011). 
 
Lymphovascular space involvement  
!
In a few studies the significance of lymphovasclular space involvement (LVI) in cases of US 
has been evaluated. It has been shown to be a marker of recurrence and relatively poor 
survival among CS and LMS patients (Major et al. 1993, Mayerhofer et al. 1999, Yamada et 
al. 2000). 
 
Mitotic index 
!
The mitotic index (MI) represents the number of mitotic figures per 10 HPFs in the most 
active area. The prognostic relevance of the MI in the sarcomatous component of CSs has not 
been established, but it has been reported to be a significant prognostic marker in cases of 
LMS and ESS. However, MI cut-off values have varied in different studies (Wolfson et al. 
1994, Gadducci et al. 1996, Nordal et al. 1996, Abeler et al. 2009, Ayhan et al. 2009, 
D'Angelo et al. 2011, Gadducci 2011).  
 
Stage 
!
Stage is the strongest and most important prognostic variable in connection with all subtypes 
of USs (Gadducci 2011). In cases of CS, LMS and ESS, stage has been found to be an 
independent prognostic factor as regards survival (Chauveinc et al. 1999, Chan et al. 2008, 
Kapp et al. 2008, Nemani et al. 2008, Abeler et al. 2009, Gonzalez Bosquet et al. 2010). 
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Tumor necrosis 
!
The presence of tumor cell necrosis has been independently associated with worse prognosis 
among patients with ESS (Abeler et al. 2009). This pathological feature has also been linked 
to prognosis of LMS patients (Ip and Cheung 2011), but the findings are inconsistent (Abeler 
et al. 2009). 
 
Tumor size and myometrial invasion 
!
Tumor size (cut-off values 50, 100 and 110mm) has been reported to be an independent 
prognostic factor as regard LMS and ESS (Nordal et al. 1996, Wu et al. 2006, Abeler et al. 
2009, D'Angelo et al. 2011). In cases of CS and ESS, the depth of myometrial invasion has 
been found to be of prognostic relevance (mostly in univariate analysis) (Major et al. 1993, 
Marth et al. 1997, Bodner et al. 2001). 
 
Bilateral salpingo-oophorectomy 
!
The prognostic relevance of BSO has been assessed only among patients with LMS and ESS, 
who in general are younger than CS patients. The impact of oophorectomy on the survival of 
LMS patients aged less than 50 years has been reported in a few studies (Gadducci et al. 
1996, Giuntoli et al. 2003, Kapp et al. 2008): preservation of the ovaries was not associated 
with negative survival in this subgroup of patients. On the other hand BSO is thought to be 
mandatory as regards ESS patients (Li et al. 2008, Gadducci 2011, Beck 2012). Some reports, 
however, have indicated that ovarian preservation has no negative influence on the survival of 
patients with early-stage ESS (Amant et al. 2007, Chan et al. 2008, Shah et al. 2008, Amant et 
al. 2009a). 
 
Lymph node status and lymphadenectomy 
!
The prognostic value of lymph node status and the LND in cases of different US subtypes is 
ambiguous (Gadducci 2011). In a study by Kokawa et al., LND was performed in 42% of 
patients with all US subtypes without any statistically significant survival benefit (Kokawa et 
al. 2006).  
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Carcinosarcoma patients with positive lymph node status at the time of primary surgery have 
shown both poorer survival (Galaal et al. 2009) and survival equal to that in lymph node 
negative patients (Gonzalez Bosquet et al. 2010). LND has been associated with improved 
overall survival in cases of stage I–III CS (Nemani et al. 2008). The lymph node count (< 11 
lymph nodes versus ≥ 11) has been found to be associated with a risk of recurrence and with 
survival in stage I–II CS (Temkin et al. 2007). However, such an association (< 12 lymph 
nodes versus ≥ 12) was not seen in stage I–III CSs in SEER data (Nemani et al. 2008). 
Kapp et al. reported that the 5-year disease-specific survival of patients with LMS was 26% in 
cases with lymph node metastases compared with 64.2% in patients without lymph node 
metastases (p < 0.001) in univariate analysis, but lymph node status was not associated with 
survival in multivariate analysis (Kapp et al. 2008). In other studies, LND has had no effect 
on the survival of LMS patients (Giuntoli et al. 2003, Sagae et al. 2004, Ayhan et al. 2009).   
In 2008, Chan et al. reported that positive lymph node status at the time of surgery in cases of 
low- and high-grade ESS (n = 831) was associated with poorer survival, when looking at 
SEER data from 1988 to 2003 (Chan et al. 2008). In the same year, Shah et al. evaluated low- 
and high-grade ESSs (n = 970) independently in another SEER study and reported the 
opposite result among low-grade ESS patients (Shah et al. 2008). However, both groups of 
investigators concluded that LND had no impact on survival of ESS patients (Chan et al. 
2008, Shah et al. 2008).  
A summary of prognostic factors is presented in Table 11. 
Table 11. Patient-, disease-, and treatment-related factors and their effects on prognosis of 
patients with uterine sarcoma (US) 
Factor Effect on prognosis Subtype of US 
Patient-related   
- Age Older age → worse prognosis All subtypes 
- Ethnic background Black race → worse prognosis All subtypes 
- Parity 0-parity → worse prognosis ESS 
Disease-related   
- Grade Higher grade → worse prognosis LMS 
- Histology See text  
- Immunohistochemistry See text  
- LVI LVI+ → worse prognosis CS, LMS 
- MI Higher MI→ worse prognosis LMS, ESS 
- Stage Higher stage → worse prognosis All subtypes 
- Tumor necrosis Necrosis present → worse prognosis LMS, ESS  
- Tumor size Larger tumor → worse prognosis LMS, ESS 
- Myometrial invasion Deep myometrial invasion → worse prognosis CS, ESS 
Treatment-related   
- BSO* BSO done → better prognosis 
BSO done or not → no effect on prognosis 
ESS** 
LMS# 
- Lymph node status  LNM + → worse prognosis CS 
- Lymphadenectomy LND done→ better prognosis CS 
CS = carcinosarcoma, LMS = leiomyosarcoma, ESS = endometrial stromal sarcoma, *with premenopausal 
patients, **no effect in early-stage ESS, #in early-stage LMS, LVI = lymphovascular space involvement, MI = 
mitotic index, BSO = bilateral salpingo-oophorectomy, LNM = lymph node metastasis 
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CONCLUSIONS OT THE LITERATURE REVIEW 
!
Only a few etiological factors are known, and diagnostics, management and prognostic factors 
of these malignancies have been debated for years. The treatment recommendations of USs 
are mainly based on small phase II-III trials, retrospective studies, case-reports and case 
series. The roles of environmental and work-related factors in the induction of USs are mostly 
unknown and only one study on the risk of second primary cancers after US has been 
published. In the present study we tried to clarify these issues.  
 
!
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AIMS OF THE STUDY 
 
The present study was undertaken to investigate the clinical behavior and prognostic factors 
of CS, LMS and ESS and elucidate epidemiological aspects of LMS and ESS. 
 
Specific aims were to evaluate 
 
1.  trends in incidence and occupational variation in the risk of uterine LMS and ESS in the 
Nordic countries (I) 
 
2. retrospectively the clinical data on uterine CS, LMS and ESS patients treated at Helsinki 
University Central Hospital between 1990 and 2001 (II) 
 
3. immunohistochemical expression of ten oncoproteins in uterine CS, LMS and ESS and 
assess their relationship to patient survival (III) 
 
4. the incidence of second primary malignancies after US (IV) 
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MATERIALS AND METHODS 
!
These studies were undertaken during 2003–2011 at Helsinki University Central Hospital 
(HUCH) and approved by the Ethics Committee of the Department of Obstetrics and 
Gynecology, and the head of the Department of Obstetrics and Gynecology, and with the 
permission of the Ministry of Social Affairs and Health. Studies I and IV have been done in 
cooperation with all Nordic Cancer Registries and International Agency for Research and 
Cancer (IARC). 
 
STUDY MATERIAL 
!
The study material is summarized in Table 12. 
 
Table 12. Study material 
 
Study All 
cases, 
n 
CS, n LMS, 
n 
ESS, 
n 
Study period/ 
location 
Source of material 
I 1913 NR 1184 
373 
352 
26 
433 
729 
263 
194 
10 
262 
1978–2007 
Finland 
Denmark 
Iceland 
Norway 
NORDCAN database 
I 1671 NR 1163 508  NOCCA database # 
  NR 494 219 1971–2005, 
Finland 
 
  NR 388 130 1961–2003, 
Norway 
 
  NR 281 159 1993–2005, 
Sweden 
 
II 100 40 39 21 1990–2001, 
Finland 
Patient registry of the Department of 
Obstetrics and Gynecology, HUCH  
III 65 28 28 9 1990–2001, 
Finland  
Patient registry of the Department of 
Obstetrics and Gynecology, HUCH  
IV 8606 4342* 3507 757 1943–2000, ## Thirteen cancer registries ## 
NR = not reported, NOCCA = Nordic Occupational Cancer Study, HUCH = Helsinki University Central 
Hospital, * Other uterine sarcomas, # Data includes women aged 30–64 years at population censuses of 1960, 
1970, 1980 or 1990, ## Finland, Denmark, Sweden, Norway, Iceland, Scotland, Spain, Slovenia, Canada (three 
centers), Australia and Singapore 
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Study I  
!
In this study the incidences of uterine LMS (n = 1184) and ESS (n = 729) were calculated for 
five-year periods from 1978–1982 to 2003–2007 and for five-year age groups by means of the 
NORDCAN database (www.ancr.nu; (Engholm et al. 2010b)), which includes detailed 
information on cancer incidence, mortality and prevalence in each of the Nordic countries. 
Incidence rates for the US categories could not be calculated for Sweden.  
Occupational variation in the risks of uterine LMS and ESS was analyzed from the Nordic 
Occupational Cancer Study (NOCCA) database. This cohort comprised 6.4 million women 
aged 30–64 years at population censuses of 1960, 1970, 1980 or 1990: 1.7 million in Finland, 
1.3 million in Norway and 3.4 million in Sweden (Pukkala et al. 2009). The follow-up periods 
concerning cancer incidence were 1971–2005 in Finland, 1961–2003 in Norway and 1993–
2005 in Sweden. During the follow-up periods, 1163 LMS and 508 ESS cases were detected 
in Finland, Norway and Sweden. The information on the occupation of each person was 
provided via free text in self-administered questionnaires: it was then centrally coded and 
computerized in the censuses of each country. Concerning NOCCA data, occupations were 
reclassified into 53 categories and one group of economically inactive persons (Table 13, 
(Pukkala et al. 2009)). 
 
 
Table 13. Occupational categories used in NOCCA 
 
1. Technical 
workers etc 
2. Laboratory 
assistants 
3. Physicians 
4. Dentists 
5. Nurses 
6. Assistant nurses 
7. "Other  
health workers" 
8. Teachers 
9.Religious 
workers etc 
10.Artistic workers 
11.Journalists 
12.Administrators 
13.Clerical 
workers 
14.Sales agents 
15.Shop workers 
16.Farmers 
17.Gardeners 
18.Fishermen 
19.Forestry 
workers 
20.Miners and 
quarry workers 
21.Seamen 
22.Transport 
workers 
23.Drivers 
24.Postal workers 
25.Textile 
workers 
26.Shoe and 
leather workers 
27.Smelting 
workers 
28.Mechanics 
29.Plumbers 
30.Welders 
31.Electrical 
workers 
32.Woodworkers 
33.Painters 
34."Other 
construction 
workers" 
35.Bricklayers 
36.Printers 
37.Chemical 
process workers 
38.Food workers 
39.Beverage 
workers 
40.Tobacco 
workers 
41.Glass makers 
etc 
42.Packers 
43.Engine 
operators 
44.Public 
safety workers 
45.Cooks  
and stewards 
46.Domestic 
assistants 
47.Waiters 
48.Building 
caretakers 
49. Chimney 
sweeps 
50. Hairdressers 
51. Launderers 
52.Military 
personnel 
53."Other 
workers" 
54.Economically 
inactive* 
* This group includes housewives, early pensioners, students and persons on social support. 
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Studies II and III 
!
For these two studies, medical records were reviewed and data collected concerning all 
uterine sarcomas (n = 100) treated during a 12-year period (1990 to 2001) at HUCH. The 
head of the Department of Obstetrics and Gynecology at HUCH approved the study design 
(chart review) and the Ethics Board of HUCH approved the IHC analysis of tissue samples. 
Follow-up data was acquired from district hospitals with approval from the Ministry of Social 
Affairs and Health.  
For Study II, all cases of uterine CS (n = 40), LMS (n = 39) and ESS (n = 21) were included. 
A pathologist at our institution made the diagnosis of US either at the time of primary 
operation or on evaluation of tumor slides. Our pathologist (R.B.) reviewed the 
histopathology slides in terms of two level grading systems in Study II. CS was considered a 
high-grade tumor (Tavassoli and Devilee 2003, Abeler et al. 2009) and LMS was defined as 
low-grade or high-grade depending on cellularity, cellular atypia, mitotic activity, vascular 
space involvement and necrosis (Studies II and III) (Tavassoli and Devilee 2003). The main 
criteria for grading of LMS were tumor necrosis and mitotic count (low-grade tumors: 
significant atypia, no tumor necrosis and mitotic count < 15–20/10 HPFs, and high-grade 
tumors: significant atypia, tumor necrosis and/or mitotic count > 15–20/10 HPFs). 
Traditionally, ESS has been divided into low- and high-grade tumors, mainly according to 
mitotic activity and this grading system was used in Study II.  
For Study III, there was sufficient histological material available for IHC analysis and slide 
review in 67 cases. In the study, one representative block per case was selected for 
immunohistochemistry. Even though the tumor slides had been assessed in a two-grade 
system in Study II, the diagnosis of four high-grade ESS tumors changed in re-evaluation for 
Study III. One of the tumors turned out to be adenosarcoma, one was an undifferentiated 
endometrial sarcoma, and there were two carcinosarcomas. The low-grade tumor definition of 
ESS was applied in study III (Tavassoli and Devilee 2003, Abeler et al. 2009). For final 
analysis, 65 uterine sarcomas (28 CSs, 28 LMSs and 9 ESSs) were chosen.  
Times to recurrence (Study II), progression (Study II), death (Study II and III) and latest 
contact (Studies II and III) were noted. The cut-off point for survival analysis was December 
31, 2005 in Study II and April 30, 2008 in Study III. Stage was defined by means of the 
modified FIGO criteria for endometrial adenocarcinoma (International Federation of 
Gynecology and Obstetrics 2006).  
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Study IV 
!
In this multi-center study of second primary cancers, data was collected from 13 cancer 
registries – in Finland, Denmark, Sweden, Norway, Iceland, Scotland, Spain, Slovenia, 
Canada (three centers), Australia and Singapore coordinated by IARC. The cohort comprised 
8606 women with a first US (LMS n = 3507, ESS n = 757 and other or undefined US n = 
4342) and represented 56823 person-years of follow-up. The majority of USs was from 
Europe (79%).  
 
The category of other or undefined uterine sarcomas included carcinosarcomas, 
adenosarcomas, undifferentiated endometrial sarcomas and other uterine sarcomas. No 
treatment data for US were available. 
 
METHODS 
!
Statistical analyses 
!
Studies I and IV 
In Study I, standardized incidence ratios (SIRs) for LMS and ESS by country and 
occupational category were computed. The SIR is the ratio of observed (Obs) and expected 
(Exp) number of cancer cases. The expected numbers were based on the cancer incidence 
rates of the entire national female population. For SIRs, exact 95% confidence intervals were 
calculated assuming a Poisson distribution of the observed cases. SIRs for US could not be 
calculated for Denmark and Iceland. 
 
In Study IV all cases of US were followed up in connetion with second primary cancer from 
the date of first diagnosis (1943–2000), to the date of second primary cancer (1943–2000), the 
date of death, the date of migration or the end of follow-up (1992–2000). The number of 
second primary cancers observed was compared with the expected number of cancers 
calculated from accumulated person-years among females with first US, specific for each 
cancer registry, and five-year age and calendar-periods and respective primary incidence rates 
in the national female populations (excluding other cancers of female genital organs). The 
SIRs were stratified for time since US diagnosis, for calendar-period of US and for age at US 
diagnosis. Poisson regression analyses were carried out for selected cancer sites to quantify 
the independent risk ratios (RRs) related to age and calendar period at US diagnosis and time 
since US diagnosis. 
 
 43 
 
Studies II and III 
In both studies, survival curves were generated by using the Kaplan–Meier method, and 
median survival times with 95% confidence intervals (95% CIs) were given. Comparison of 
survival curves between groups (Study II) and between negative and positive marker status 
(Study III) was performed using the log-rank test. Those variables found to be statistically 
significant in univariate analysis in Study II were examined by multivariate analysis using 
Cox´s proportional hazards regression model: hazard ratios and their 95% CIs were reported. 
In Study III, survival analyses were carried out separately for each uterine sarcoma type, but 
because of the small sample size, results were not reported for ESS. 
For Study III, associations between the type of uterine sarcoma and IHC markers were 
evaluated using cross-tabulation and Fisher´s exact χ2 -test. Androgen receptors and c-kit 
were not tested because all AR staining results were negative, and there were only two cases 
of positive c-kit staining. 
Statistical analysis was performed using SPSS statistical software for Windows versions 13.0 
and 16.0 (SPSS INC., Chicago, IL). A p value of less than 0.05 was considered statistically 
significant for all tests. 
 
Immunohistochemical analysis 
!
For ICH in Study III, formalin-fixed, paraffin-embedded tissue samples of all uterine 
sarcomas were used. Staining was performed by using a LabVision immunostainer 
(LabVision, CA, USA). Antigen retrieval was carried out in Tris-EDTA buffer, pH 9.0. It was 
done in a microwave oven for 24 minutes at 900 watts, cooling for 20 minutes at room 
temperature. The IHC studies involved a polymer-based detection system (Envision, K5007, 
DakoCytomation) with diaminobenzidine chromogen. The primary antibodies used in Study 
III are listed in Table 14. 
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Table 14. Antibodies used for immunohistochemical analysis in Study III 
 
Antibody Dilution Manufacturer / product number / clone 
MIB1* 1:200 DakoCytomation / (M7240) / MIB-1 
p53 1:150 DakoCytomation / (M 7001) / DO-7 
CD10 1:20 Novocastra / (NCL-CD10-270) / 56C6 
CD44 1:50 DakoCytomation / (M7082) / DF1485 
Desmin 1:100 DakoCytomation / (M0760) / D33 
Actin 1:100 DakoCytomation / (M0760) / 1A4 
Estrogen receptor-α 1:50 Novocastra / (NCL-ER-6F11) / 6F11 
Androgen receptor 1:25 Novocastra / (NCL-AR-318) / AR27 
Progesterone receptor  1:200 DakoCytomation / (M3569) / PgR636 
c-kit 1:300 DakoCytomation / (A4502) / polyclonal 
*Antibody against Ki-67 
 
 
Immunoreactivity was scored semiquantitatively. The intensity of the immunoreaction was 
rated as zero to three (0 = cannot be assessed, 1= negative, 2 = positive with regard to p53, c-
KIT, CD10, CD44, desmin, SMA, AR, ER-α and PR; 0 = cannot be assessed, 1 = < 5% 
positive, 2 = 5–50% positive, 3 = > 50% positive with regard to Ki-67). Two investigators 
(R.B. and R.K-K.) blinded to the clinical data came to a consensus of opinion concerning the 
stained slides.  
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RESULTS 
  
INCIDENCE AND OCCUPATIONAL RISKS OF LMS AND ESS IN NORDIC 
COUNTRIES 
!
The incidence of LMS was relatively stabile over the years in all four countries (Figure 5). 
The rates in Iceland and Norway were about 0.5 per 100,000, slightly higher than in Denmark 
and Finland. The rates for ESS were about 0.2 per 100,000, but with some suggestion of an 
increase (Figure 6). The incidence of LMS was highest in the age groups of 45–59 years 
(Figure 7). The incidence rates of ESS were constant from the age group of 45–49 years 
onwards. 
 
 
Figure 5. Incidence of uterine leiomyosarcoma in Iceland, Denmark, Finland and  
Norway, by 5-year periods; adjusted for age to the World Standard Population*  
 
 
*Tabulation based on NORDCAN data (Engholm et al. 2010b) 
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Figure 6. Incidence of endometrial stromal sarcoma in Iceland, Denmark, Finland  
and Norway, by 5-year periods; adjusted for age to the World Standard Population* 
 
 
*Tabulation based on NORDCAN data (Engholm et al. 2010b) 
 
Figure 7. Age-specific incidence rates of uterine leiomyosarcoma and endometrial  
stromal sarcoma in Iceland, Denmark, Finland and Norway from 1978 to 2007* 
 
 
LMS = leiomyosarcoma, ESS = endometrial stromal sarcoma 
*Tabulation based on NORDCAN data (Engholm et al. 2010b) 
 47 
 
In the NOCCA study, including Finland, Norway and Sweden, the occupational groups with 
significantly increased SIRs of LMS were shoe and leather workers, farmers and teachers. 
The only occupational group with a significantly decreased SIR was domestic assistants 
(Table 15). For ESS, no occupations with elevated SIRs were observed. 
 
 
Table 15. Observed numbers (Obs) and statistically significantly increased or decreased 
standardized incidence ratios (SIRs, p < 0.05) of uterine leiomyosarcoma among women in 
Finland (1971–2005), Norway (1961–2003) and Sweden (1993–2005), by occupational 
category 
 
95% confidence intervals (95% CI) of the SIR are given for the total of the three countries.  
Occupational category Finland  Norway  Sweden  Total 
Obs SIR   Obs SIR   Obs SIR   Obs SIR  95%CI 
Shoe and leather workers 3 1.43     3 4.55     2 6.16    8 2.59   1.12 — 5.11 
Farmers 22 1.73     21 1.56     2 1.19    45 1.62   1.18 — 2.17 
Teachers 27 1.57     13 0.99     26 1.49    66 1.38   1.07 — 1.76 
Domestic assistants 7 0.71     9 0.73     7 0.51    23 0.64   0.41 — 0.96 
All categories 494 1.00   388 1.00   281 1.00   1163 1.00  Ref. 
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CLINICAL AND PROGNOSTIC FACTORS AND SURVIVAL IN CASES OF CS, 
LMS AND ESS 
 
Clinical findings 
Patient demographics and clinical findings are summarized in Table 16. 
Table 16. Patient characteristics as regards different types of uterine sarcoma 
 
Characteristic CS (n = 40) LMS (n = 39) ESS (n = 21) All (n = 100) 
Median age,  
years (range) 
65 (42–89) 52 (27–86) 52 (37–83) 60 (27–89) 
Stage     
- I 16 23 15 54 
- II 3 2 0 5 
- III 15 9 4 28 
- IV 6 3 2 11 
- Not known 0 2 0 2 
Grade     
- Low-grade 0 24 13 37 
- High-grade 40 15 8 63 
Primary operation 39 38 21 98 
- Hysterectomy 36 33 21 90 
- Other operation 3 5 0 8 
BSO done 38 33 18 89 
Lymph  
node evaluation 
24 
 
15 13 52 
 
- Not done 16 24 8 48 
- Only biopsies 11 8 4 23 
- Done 13 7 9 29 
LNM 6 0 1 7 
Adjuvant CT (%) 13 (33%) 21 (54%) 7 (33%) 41 
- CEP 13 2 7 22 
- EI 0 19 0 19 
Adjuvant RT (%) 28 (70%) 5 (13%) 18 (86%) 51 
- Pelvic 3 4 3 10 
- Pelvic + BT 15 1 9 25 
- BT 10 0 6 16 
Response (%)     
- Complete response 33 (82%) 29 (74%) 18 (86%) 80 
- Partial response 1 (3%) 3 (8%) 0 (0%) 4 
- Progressive disease 6 (15%) 7 (18%) 3 (14%) 16 
Recurrence (%) 16 (48%) 16 (55%) 8 (44%) 40 (50%) 
BSO = bilateral salpingo-oophorectomy, LNM = lymph node metastasis, CT = chemotherapy, RT = 
radiotherapy, BT = brachytherapy, CEP = cisplatin + epirubicin + cyclophosphamide, EI = etoposide + 
ifosfamide, Values are given as number of observations (n), if not otherwise stated. 
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Survival 
The median disease-specific survival time for all patients was 65 months (95%CI 22–108 
months). The 2-, 5- and 10-year overall survival rates were 62%, 51% and 38% and disease-
specific survival rates were 64%, 56% and 44%. Five-year survival in cases of ESS (65%) 
was better than in cases of LMS (57%) and CS (49%), but when comparing survival times 
there were no statistically significant differences between histological types (p = 0.613, Figure 
8). Lower stage (p < 0.001), lower grade (p = 0.009), younger age (p < 0.001) and small 
tumor size (p = 0.050) were all associated with statistically significantly improved disease-
specific survival in univariate analysis. Delivery status was also associated with disease-
specific survival (p = 0.001); those having more deliveries had a worse disease-specific 
survival.  
 
Figure 8. Disease-specific survival as regards uterine carcinosarcoma, leiomyosarcoma and 
endometrial stromal sarcoma (Kaplan–Meier analysis) 
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The median time to recurrence was 14 months (range 4–116 months) for all types of relapsed 
uterine sarcomas, 11 months (range 4–80 months) for CSs, 19 months (range 6–116 months) 
for LMSs and 15 months (range 4-32 months) for ESSs. As calculated for relapsing patients 
only, the median progression-free survival was 8 months (range 2–82 months). 
In multivariate analysis, stage, tumor size and delivery status were found to have independent 
influences on both overall and disease-specific survival, and age only on overall survival 
(Table 17).  
  
 
Table 17. Multivariate analysis: overall and disease-specific survival in Study II (n = 64) 
 
Variable Overall survival 
Hazard ratio (95%CI) 
p Disease-specific survival 
Hazard ratio (95%CI) 
p 
Age (years) 
 < 50  
 50–59 
 60–69 
 70–79 
 80– 
 
1.0 (ref.) 
2.6 (0.6–11.8) 
2.2 (0.5–10.2) 
6.9 (1.1–41.5) 
17.0 (2.6–109.5) 
0.016  
1.0 (ref.) 
2.5 (0.6–11.7) 
2.3 (0.5–11.3) 
7.6 (1.2–47.9) 
11.1 (1.5–82.7) 
0.100 
Stage 
 I 
 II 
 III 
 IV 
 
1.0 (ref.) 
4.4 (0.6–29.5) 
4.9 (1.7–14.3) 
38.2 (9.4–155.5) 
< 0.001  
1.0 (ref.) 
3.7 (0.5–30.0) 
3.5 (1.0–11.4) 
37.6 (8.4–169.3) 
< 0.001 
Tumor size 
 < 5 cm 
 5–10 cm 
 > 10 cm 
 
1.0 (ref.) 
2.4 (0.9–6.0) 
7.8 (2.5–24.0) 
0.001  
1.0 (ref.) 
2.6 (1.0–7.1) 
10.5 (3.1–35.1) 
0.001 
Delivery status 
 no pregnancies  
 one delivery 
 two deliveries 
 three deliveries 
 ≥ four deliveries 
 
1.0 (ref.) 
1.8 (0.4–7.4) 
1.5 (0.4–5.2) 
11.4 (2.7–47.8) 
1.4 (0.3–5.6) 
0.009  
1.0 (ref.) 
2.3 (0.5–11.2) 
2.0 (0.5–7.5) 
15.5 (3.4–69.7) 
1.3 (0.3–6.0) 
0.005 
CI = confidence interval, ref. = reference category 
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IMMUNOHISTOCHEMICAL MARKERS AND THEIR PROGNOSTIC 
SIGNIFICANCE IN CASES OF UTERINE CS, LMS AND ESS 
!
Immunohistochemical analysis  
The expression of Ki-67, p53, CD10, CD44, desmin, SMA, ER-α, AR, PR and c-KIT was 
evaluated by immunohistochemistry. All cases were AR-negative, and c-kit was weakly 
positive in only two cases of ESS. Smooth muscle actin was statistically significantly 
associated with the type of sarcoma (p = 0.003); in LMS, more cases stained positively (78%) 
than in other sarcoma types. Associations between Ki-67, desmin and PR vs. type of sarcoma 
were of borderline significance. In IHC analysis, there were a few cases that could not be 
evaluated (two with regard to desmin and SMA, three with regard to Ki-67, p53, CD10, CD 
44 and PR, and five with regard to ER-α). The expression of IHC markers (except AR and c-
kit) according to the type of uterine sarcoma is summarized in Table 18.  
Table 18. Immunohistochemical (IHC) profiles according to uterine sarcoma subtype 
 
 IHC marker CS n = 26–28* LMS n = 26–28* ESS n = 8–9*  All   
 n (%) n (%) n (%) n (%) p 
Ki-67     0.069 
<5% pos 3 (11) 9 (33) 3 (37,5) 15 (24)  
5–50% pos 17 (63) 15 (56) 2 (25) 34 (55)  
>50% pos 7 (26) 3 (11) 3 (37,5) 13 (21)  
p53     0.785 
neg 19 (70) 20 (74) 7 (88) 46 (74)  
pos 8 (30) 7 (26) 1 (12) 16 (26)  
CD10     0.532 
neg 12 (44) 16 (59) 3(38) 31 (50)  
pos 15 (56) 11 (41) 5 (62) 31 (50)  
CD44     0.136 
neg 11 (41) 17 (63) 6 (75) 34 (55)  
pos 16 (59) 10 (37) 2 (25) 28  (45)  
Desmin     0.075 
neg 19 (68) 11 (41) 6 (75) 36 (57)  
pos 9 (32) 16 (59) 2 (25) 27 (43)  
SMA     0.003 
neg 17 (61) 6 (22) 6 (75) 29 (46)  
pos 11 (39) 21 (78) 2 (25) 34 (54)  
Estrogen receptor-α   0.258 
neg 20 (77) 15 (58) 4 (50) 39 (65)  
pos 6 (23) 11 (42) 4 (50) 21 (35)  
Progesterone receptor    0.084 
neg 20 (74) 12 (44) 4 (50) 36 (58)  
pos 7 (26) 15 (56) 4 (50) 26 (42)  
CS = carcinosarcoma, LMS = leiomyosarcoma, ESS = endometrial stromal sarcoma, SMA = smooth muscle 
actin, *The number of cases varies because in each group there were instances of IHC staining that could not be 
analyzed. 
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Survival 
The median disease-specific survival time for all patients was 66 months (95% CI 0–152 
months). ER-α- and PR-positivity were associated with statistically significantly better 
disease-specific survival times in cases of LMS (Figures 9 and 10). Oncoprotein p53 
overexpression was associated adversely with the survival of LMS patients (p = 0.011). 
Strong Ki-67 expression in cases of CS was associated with a tendency to show worse 
disease-specific survival (p = 0.055, Table 19). No relationship was found between the 
markers CD10, CD44, desmin and SMA, and survival.  
 
Table 19. Median disease-specific survival times according to IHC staining intensity of Ki-67, 
p53, estrogen receptor-α (ER-α) and progesterone receptor (PR) in cases of uterine 
carcinosarcoma (CS) and leiomyosarcoma (LMS) 
 
Variable CS 
 
n 
Median survival time, 
months (95%CI) 
 
 
p 
LMS 
 
n 
Median survival time, 
months (95%CI) 
 
 
p 
Ki-67   0.055   0.188 
<5% pos 3 41 (0-92)  9 *  
5–50% pos   17 168 (0-349)  15 64 (33-96)  
>50% pos 7 7 (7-8)  3 27 (0-61)  
p53   0.746   0.011 
neg 19 23 (0-57)  20 123 (#)  
pos 8 29 (0-176)  7 11 (3-20)  
ER-α   0.482   0.005 
neg 20 20 (6-33)  15 41 (1-80)  
pos 6 102 (0-284)  11 *  
PR   0.896   0.012 
neg 20 20 (6-33)  12 53 (16-91)  
pos 7 41 (0-104)  15 *  
CI = confidence interval, *Cannot be defined, because more than 50% were alive at the cut-off point for survival 
analysis, #Cannot be calculated. 
 
!
!
!
!
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Figure 9. Disease-specific survival of patients with uterine leiomyosarcoma according to 
estrogen receptor-α status in Study III 
 
!
 
Figure 10. Disease-specific survival of patients with uterine leiomyosarcoma according to 
progesterone receptor status in Study III 
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SECOND PRIMARY MALIGNANCIES AFTER UTERINE SARCOMA 
!
There were 499 cancer cases observed after first US: 215 after LMS, 36 after ESS and 248 
after other or undefined US. The SIR of a second primary cancer at all sites combined 
(excluding female genital organs) after a US of any type was 1.26 (95%CI 1.16–1.38). 
Significantly elevated SIRs were seen in connection with cancers of the mouth and pharynx, 
colorectum, lung, breast, urinary bladder, kidney, and thyroid gland, and soft tissue sarcoma 
(Table 20). There were no second cancers with significantly reduced SIRs after US diagnosis. 
 
Significantly elevated SIRs after first uterine LMS were seen for all sites combined, for 
rectum and lung cancer, and for soft tissue sarcoma (Table 21). In the ESS subgroup, none of 
the SIRs of second primary cancer reached statistical significance. In the group of patients 
with other or undefined USs, SIRs were elevated for colorectal, lung, urinary bladder, kidney 
and thyroid cancer (Table 22).  
 
 
 
Table 20. Second primary cancer sites with statistically significantly elevated standardized 
incidence ratios (SIRs) among 8 606 women with a first primary uterine sarcoma 
 
Cancer site (ICD-9) Observed* SIR 95%CI 
All malignant (140-208)** 499 1.26 1.16–1.38 
Soft tissue sarcoma (171) 10 5.23 2.51–9.62 
Thyroid gland (193) 12 2.74 1.42–4.79 
Mouth and pharynx (140-149) 13 2.16 1.15–3.69 
Kidney (189, excluding 189.3-4) 21 2.00 1.24–3.06 
Urinary bladder (188, 189.3-4) 17 1.74 1.02–2.79 
Lung (162) 48 1.73 1.27–2.29 
Colorectal (153,154) 86 1.60 1.28–1.98 
Breast (174) 132 1.25 1.05–1.49 
*Observed numbers of subsequent primary cancer cases, CI = confidence interval, **Excluding other cancers of 
female genital organs 
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Table 21. Second primary cancer sites with statistically significantly elevated standardized 
incidence ratios (SIRs) among 3 507 women with a first primary uterine leiomyosarcoma 
 
Cancer sites (ICD-9) Observed* SIR 95%CI 
All malignant  (140–208)** 215 1.28 1.12–1.46 
Soft tissue sarcoma (171) 8 8.79 3.80–17.3 
Colorectal (153,154) 38 1.85 1.31–2.53 
Lung (162) 19 1.73 1.04–2.70 
*Observed numbers of subsequent primary cancer cases, CI = confidence interval, **Excluding other cancers of 
female genital organs 
 
 
Table 22. Second primary cancer sites with statistically significantly elevated standardized 
incidence ratios (SIRs) among 4 342 women with a first primary other uterine sarcoma 
 
Cancer sites (ICD-9) Observed* SIR 95%CI 
All malignant  (140–208)** 248 1.24 1.09–1.40 
Thyroid gland (193) 7 4.05 1.63–8.34 
Kidney (189, excluding 189.3–4) 12 2.28 1.18–3.99 
Bladder (188, 189.3, 189.4) 11 2.04 1.02–3.64 
Lung (162) 25 1.71 1.11–2.52 
Colorectal (153, 154) 43 1.46 1.06–1.97 
*Observed numbers of subsequent primary cancer cases, CI = confidence interval, **Excluding other cancers of 
female genital organs 
 
The SIR for second cancer (all sites combined) was highest if age at US diagnosis was less 
than 50 years, the year of US diagnosis was 1975–1983 or if the time since US diagnosis was 
10 or more years. For breast cancer, SIRs were highest if the age at US diagnosis was 60 
years or more. The result was the same in multivariate analysis, adjusting for the year of US 
diagnosis and time since US diagnosis. For colorectal cancer, SIRs increased with increasing 
time since diagnosis of US, but none of the variables had significant independent effects on 
risk in multivariate analysis. However, there was still a suggestive trend towards an increasing 
risk of colorectal cancer with increasing time since diagnosis of US. For kidney cancer, SIRs 
were highest if the age at US diagnosis was less than 50 years and the time since diagnosis 
was less than one year. The same pattern as regards age and time since US diagnosis was 
detected in multivariate analysis. For the other sites, the numbers of cases were too small to 
allow multivariate analysis. The data is summarized in Tables 23 and 24. 
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Table 23. Observed numbers and standardized incidence ratios for second primary cancers at selected sites among 8 606 women with a first 
uterine sarcoma, by age and calendar period at uterine sarcoma diagnosis and by time since uterine sarcoma diagnosis 
 
Factor 
 
Age at US diagnosis Year of US diagnosis Years since US diagnosis  
< 50 50–59 ≥ 60 < 1975 1975–1983 1984–1990 1991 + ≤1 1–4 5–9 10+ 
All malignant 
Obs 
SIR 
95%CI 
186 136 177 223 144 86 46 45 121 93 240 
1.36 1.20 1.23 1.25 1.45 1.23 1.00 1.00 1.26 1.21 1.36 
1.17–1.56 1.01–1.41 1.10–1.42 1.10–1.42 1.22–1.70 0.98–1.51 0.73–1.33 0.73–1.34 1.04–1.49 0.98–1.48 1.20–1.54 
Colorectal 
Obs 29 25 32 41 27 12 6 5 16 17 48 
SIR 1.91 1.64 1.35 1.64 2.01 1.30 1.01 0.84 1.29 1.71 1.98 
95%CI 1.28–2.75 1.06–2.42 0.94–1.94 1.18–2.23 1.32–2.92 0.67–2.27 0.37–2.19 0.27–1.95 0.74–2.10 1.00–2.74 1.39–2.50 
Lung 
Obs 14 13 21 13 16 12 7 5 13 9 21 
SIR 1.61 1.57 1.94 1.26 2.09 2.03 1.79 1.57 1.94 1.69 1.67 
95%CI 0.88–2.70 0.84–2.69 1.20–2.97 0.67–2.16 1.19–3.39 1.05–3.54 0.72–3.69 0.51–3.67 1.03–3.32 0.77–3.21 1.03–2.55 
Breast 
Obs 53 32 47 59 36 29 8 8 35 29 60 
SIR 1.20 1.04 1.55 1.31 1.33 1.48 0.60 0.67 1.29 1.35 1.35 
95%CI 0.90–1.57 0.71–1.47 1.14–2.07 1.00–1.69 0.93–1.84 0.99–2.12 0.26–1.18 0.29–1.31 0.90–1.80 0.90–1.93 1.03–1.73 
Kidney 
Obs 10 7 4 10 6 1 4 6 5 2 8 
SIR 2.93 2.19 1.03 1.96 2.38 0.57 3.64 5.43 2.11 1.03 1.58 
95%CI 1.40–5.39 0.88–4.52 0.28–2.65 0.94-3.60 0.87–5.18 0.01–3.20 0.99–9.32 1.99–11.8 0.69–4.93 0.13–3.74 0.68–3.11 
US = uterine sarcoma, Obs = observed, SIR = standardized incidence ratio, CI = confidence interval 
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Table 24. Risk ratios for second primary cancers in selected sites among 8 606 women with a first uterine sarcoma, by age and calendar  
period at uterine sarcoma diagnosis, and by time since uterine sarcoma diagnosis 
 
Factor Breast 
 
RR (95%CI) 
 
 
p trend 
Colorectal 
 
RR (95%CI) 
 
 
p trend 
Lung 
 
RR (95%CI) 
 
 
p trend 
Kidney 
 
RR (95%CI) 
 
 
p trend 
Age at US 
diagnosis 
- <50 
- 50-59 
- ≥60 
 
 
0.63 (0.41–0.98) 
0.58 (0.36–0.93) 
1.00 (ref.) 
 
 
 
 
0.040 
 
 
1.20 (0.66–2.17) 
1.04 (0.59–1.83) 
1.00 (ref.) 
 
 
 
 
0.644 
 
 
0.94 (0.42–2.11) 
0.84 (0.40–1.76) 
1.00 (ref.) 
 
 
 
 
0.758 
 
 
7.03 (1.89–26.2) 
3.76 (1.04–13.6) 
1.00 (ref.) 
 
 
 
 
0.004 
Year of US 
diagnosis 
- <1975 
- 1975-1983 
- 1984-1990 
- >1990 
 
 
1.00 (ref.)  
0.95 (0.62–1.47) 
1.04 (0.63–1.47) 
0.45 (0.20–1.01) 
 
 
 
 
 
0.288 
 
 
1.00 (ref.) 
1.40 (0.83–2.35) 
1.02 (0.49–2.14) 
0.94 (0.35–2.53) 
 
 
 
 
 
0.787 
 
 
1.00 (ref.) 
1.76 (0.80–3.84) 
1.82 (0.70–4.75) 
1.65 (0.51–5.29) 
 
 
 
 
 
0.249 
 
 
1.00 (ref.) 
1.33 (0.46–3.90) 
0.29 (0.03–2.49) 
1.32 (0.33–5.26) 
 
 
 
 
 
0.993 
Years since 
US diagnosis 
- <1 
- 1-4 
- 5-9 
- ≥10 
 
 
0.51 (0.24–1.10)  
1.00 (ref.) 
0.97 (0.59–1.61) 
1.05 (0.65–1.70) 
 
 
 
 
 
0.333 
 
 
0.66 (0.24–1.82) 
1.00 (ref.) 
1.25 (0.62–2.53) 
1.36 (0.69–2.69) 
 
 
 
 
 
0.182 
 
 
0.80 (0.28–2.25) 
1.00 (ref.) 
0.91 (0.38–2.22) 
1.18 (0.48–2.89) 
 
 
 
 
 
0.471 
 
 
3.18 (0.95–10.6) 
1.00 (ref.) 
0.38 (0.07–2.02) 
0.34 (0.10–1.18) 
 
 
 
 
 
0.018 
RR = risk ratio, US = uterine sarcoma, CI = confidence interval, ref. = reference category 
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DISCUSSION  
!
Our study showed relatively constant incidence trends of ESS and LMS in Nordic countries 
and in connection with certain occupations, a significantly elevated incidence of LMS (I). Our 
survival rates in cases of US were comparable or even better than in earlier studies and we 
noticed that higher parity could have a negative influence on survival in cases of US (II). In 
IHC analysis, the expression of ER-α, PR and p53 was associated with survival of LMS 
patients (III). We demonstrated an increased risk of second primary malignancies following a 
diagnosis of US (IV). 
 
Strengths and limitations of the present study 
 
We had a great opportunity to use the NORDCAN and NOCCA databases, to view trends in 
incidences and occupational risks of LMS and ESS in Nordic countries, and in Study IV to 
analyze second primary malignancies after first primary US in an international multicenter 
trial coordinated by IARC. Both NORDCAN and NOCCA offered data on large cohorts of 
LMS and ESS patients, even thought we could not calculate the incidence rates for Sweden 
and SIRs for occupational category for Denmark and Iceland. An extra advantage of large 
cohorts is long follow-up times. In retrospective studies (II+III) we had a relatively large 
sample size from one institution when comparing with earlier, similar studies on USs. To the 
best of our knowledge, this is the first time that the incidence and occupational risks of uterine 
LMS and ESS have been evaluated in the Nordic countries, and it was the largest 
multinational US patient cohort ever collected for a second primary malignancy study. 
Although the results of retrospective studies should always be interpreted with caution, our 
data on survival and prognostic factors are comparable with those in earlier retrospective 
studies on USs. 
A limitation of Studies I and IV is the lack of individual data on risk factors and treatment 
methods, and results should be interpreted with caution. There is always the possibility of 
coding problems when data is collected from 13 cancer registries, although a conservative 
coding principle was used. The retrospective study design and the small number of patients in 
different US subgroups are limitations of Studies II and III, but an attempt has been made to 
take these factors into account in assessing and discussing the results. For the reader it is 
important to know that we have used the term adjuvant therapy in connection with all patients 
who have been treated by means of first-line therapy. Comparison of IHC analyses in 
different studies is also problematic because variations in staining may be the result of many 
factors and the cut-off values concerning staining can radically differ. In addition the analysis 
of slides is a subjective method.  
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The classification of USs changed during this research project. Uterine CS has been 
reclassified as a metaplastic carcinoma of endometrial origin (McCluggage 2002c) and ESS 
as a low-grade malignancy (Tavassoli and Devilee 2003). Undifferentiated endometrial 
sarcoma has replaced the term high-grade ESS. However, CS was selected in two 
retrospective studies (II + III) because of the study design and for historical reasons. In Study 
II, the group of “high-grade ESS” remained, but after re-evaluation of pathological slides for 
Study III, only low-grade ESS existed in the ESS group. 
 
Trends in incidences of uterine LMS and ESS in Nordic countries 
 
Very few studies exist on the incidence of USs and its change over the years (Harlow et al. 
1986, Nordal and Thoresen 1997). In our study period, the incidence rates of both LMS and 
ESS were relatively similar and constant in four Nordic Countries. Age-specific incidences of 
LMS and ESS increased up to the age groups around menopause, but decreased after the age 
of 60 in cases of LMS. Using the SEER data, Harlow et al. published a demographic study of 
1452 USs in the United States (1973–1981): the overall annual incidence of all cases of US 
was 1.7, for that of CS 0.8, for LMS 0.6 and for ESS 0.2 per 100 000. Nordal and Thoresen 
reported slightly rising trends of incidence of all USs in Norway (1956–1992): the incidence 
rate was 1.7 per 100 000 during the latest study period of 1987–1992. The authors concluded 
that raised rates are mainly explained by the increase in the occurrence of CSs. The timeframe 
of their incidence analysis is also covered by our study period. Our stable trends in LMS and 
ESS in Norway are in accordance with the findings of Nordal and Thoresen (1997). 
Comparing our rates with the incidences reported by Harlow et al., the incidence rate of LMS 
was only slightly lower in Nordic countries than in the United States in the first five-year 
study period. The difference in incidence rates of LMS was more notable when Nordic rates 
were compared with the rates in the black race subgroup of patients (0.99 per 100 000) in the 
report by Harlow et al. (Harlow et al. 1986). 
Trends in incidences of diseases or malignancies can be influenced, for example, by changes 
in risk factors among the study population, aging of the population and changes in 
diagnostics. According to NORDCAN, the estimated annual age-standardized incidence rate 
of cancer of corpus uteri has been shown as a still growing trend of +0.2% in the last 10 years 
(Engholm et al. 2010a). The use of menopausal hormone therapy increased from the late 
1970s until the late 1990s in all Nordic countries, while there was a decrease in menopausal 
hormone therapy sales in Iceland, Norway, Sweden and Finland from the year 2000 to 2005 
(Hemminki et al. 2008) following the publication of the results of the Women’s Health 
Initiative study (Rossouw et al. 2002). Hormone treatment has been associated with a risk of 
US (Schwartz et al. 1996), and the use of estradiol-progestin menopausal hormone 
replacement therapy for 5 years or longer has been connected with a two-fold risk of USs 
(Jaakkola et al. 2011). However, we did not observe any clear changes in the incidence rates 
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of LMS or ESS in these countries during the study period. Unfortunately, it was not possible 
to analyze the incidence rates of uterine CS in our study. It would have been interesting, 
because in the above-mentioned Norwegian study (1956–1992) the incidence of CS increased. 
The authors speculated that it could have been related to some environmental factors in the 
etiology of CSs (Nordal and Thoresen 1997). 
 
Diagnostic changes in pathology were introduced for LMS after the revision of WHO 
classification concerning the female genital organs in 2003 (Tavassoli and Devilee 2003, 
D'Angelo et al. 2009). It has been suggested that the new criteria have led to a reduction of 
misdiagnoses of STUMPs and leiomyoma variants such as LMSs (D'Angelo et al. 2009). 
Nordic trends in incidences of LMSs changed only slightly within the latest study period: in 
Finland and Denmark incidences decreased and in Iceland and in Norway they increased. This 
could mean that the new criteria have had a bi-directional influence on diagnostics in 
pathology – earlier diagnosis of low-grade LMS may have changed to STUMP and STUMP 
to low-grade LMS in different countries. 
 
It is a well-known fact that the Nordic population is ageing (Statistics Denmark 2010), and 
one of the risk factors for US, obesity, is becoming more and more common among women. 
We observed peak incidences of both LMS and ESS around the menopause, in which period 
of life women may experience weight gain, increases of central adipose tissue and other 
changes of body composition (Freeman et al. 2010). In the perimenopausal period the 
imbalance of secreted ovarian hormones and elevated levels of gonadotropins can 
theoretically be associated with peak incidences of LMS and ESS, much like the 
hypergonadotropic hypogonadal state is thought to be related to the peak incidence of ovarian 
cancer (Cramer 1990).  
 
In conclusion, the incidence rates of LMS and ESS showed minor differences between the 
countries and only modest changes over the study period. 
 
 
Occupational risks of uterine LMS and ESS in Nordic countries  
 
In Study I, significantly elevated incidence rates of LMS were observed among shoe and 
leather workers, farmers and teachers. No occupations with an elevated risk of ESS were 
noticed.  
We observed the highest SIR (2.59, 95%CI 1.12–5.11) for LMS among shoe and leather 
workers. Pukkala et al. also noticed a slightly elevated SIR (1.33, 95%CI 1.12–1.58) in 
connection with cervical cancer among shoe and leather workers, but no other gynecological 
cancer site or soft tissue sarcoma has been associated with this occupational group in NOCCA 
data (Pukkala et al. 2009, Riska et al. 2012). According to NOCCA job exposure matrices 
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(JEMs), shoe and leather workers are exposed to carcinogenic agents such as benzene, 
toluene, 1,1,1-trichloroethane, methylene chloride and trichloroethylene (Kauppinen et al. 
2009). Cervical cancer has been associated with occupational exposure to agents such as 
aliphatic, alicyclic, aromatic, and chlorinated hydrocarbon solvents (Weiderpass et al. 2001). 
Even though the association of LMS with shoe and leather workers may be a chance finding, 
based on only eight observed cases, occupational exposure to chemicals in the shoe and 
leather industries has been related to several cancer sites and soft tissue sarcomas (Mikoczy et 
al. 1996, Lope et al. 2009). Our result may reflect the possibility that occupational exposure 
among shoe and leather workers could be carcinogenic as regards uterine LMS.  
 
In the current study overpresentation of LMS among farmers is a unique finding compared 
with other gynecological cancer sites (Pukkala et al. 2009, Riska et al. 2012). In a recent 
NOCCA study, the risk of primary fallopian tube cancer (SIR 0.68, 95%CI 0.47–0.95) was 
reported to be significantly and consistently low for women working in farming and was 
partly explained by the higher parity of female farmers (Riska et al. 2011). Female farmers 
tend to have more childbirths than other occupational groups (Pukkala 1995, Pukkala et al. 
2009). A farmer´s occupation is related to lifestyle factors (low smoking prevalence, low 
alcohol consumption and highly physically active work) that are inversely associated with 
several cancer types (Pukkala et al. 2009). An increasing number of full-term pregnancies 
reduces the risks of endometrial cancer, ovarian cancer and primary fallopian tube cancer 
(Kvale et al. 1988, Albrektsen et al. 1995, Schwartz et al. 1996, Hinkula et al. 2002, Hinkula 
et al. 2006, Riska et al. 2007b), but its effect on the risk of US is unclear (Kvale et al. 1988, 
Schwartz et al. 1991). The mechanism of how pregnancies lower the risk of certain cancers is 
not understood. In the case of endometrial cancer, it has been thought that progesterone is the 
key inhibitor of carcinogenesis and a major endometrial tumor suppressor. Progesterone acts 
though genomic and non-genomic regulation. It promotes apoptosis, cell differentiation and 
cell cycle arrest and inhibits invasion and inflammation (Yang et al. 2011). Another suggested 
explanation has been that pregnancy and delivery could mechanically clean possible pre-
malignant uterine lining cells (Albrektsen et al. 1995). However, we speculate that these 
theories may work differently in cases of US that originate from the mesenchymal 
compartment of the uterus and express both ERs and PRs in different proportions. 
Furthermore, after several pregnancies, women tend to gain weight, which correlates with 
higher estrogen levels (Wolfe et al. 1997). Both an overweight condition and estrogen are 
considered to be potential risk factors of US. We can hypothesize that multiparity or its 
consequences may increase the risk of uterine LMS in women farmers.  
 
In agricultural work, farmers and farm workers are exposed to animal dander (dust) and 
several chemicals (Blair and Zahm 1995, Blair and Freeman 2009, Kauppinen et al. 2009). 
Animal dusts are known causes of respiratory tract irritation and allergy, and organic dusts are 
thought to represent occupational carcinogenic exposure (Laakkonen et al. 2006). In the 
Nordic countries, according to a NOCCA JEM, about 90 percent of female farmers are 
exposed to animal dust, and the level of exposure was 0.01–0.02 mg/m3 during 1945–1994 
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(Kauppinen et al. 2009). Weiderpass and co-workers have reported that women exposed to 
animal dust (furriers and fiber processors) showed a higher risk of endometrial cancer during 
the study period 1971–1995 in Finland (Weiderpass et al. 2001). Animal dust exposure might 
be related to the increased risk of LMS observed in women farmers, although the supposed 
mechanism is unclear.  
 
Although we found an increased risk of LMS among teachers, this association is difficult to 
explain. In earlier studies this occupation has been reported to be associated with elevated 
risks of breast, uterine and ovarian cancers (Bernstein et al. 2002, Pukkala et al. 2009). These 
excess risks could possibly be associated with teachers’ health habits rather than occupational 
exposure. 
  
In conclusion, the overpresentation of LMS in women exposed to leather work and women 
farmers could be assumed to be multifactorial and this finding has to be considered as a very 
preliminary one.  
 
 
Prognostic factors and survival in cases of uterine CS, LMS and ESS 
 
Prognostic factors of US help us to concentrate on appropriate postoperative management and 
research into better adjuvant therapies. In our study age, stage, tumor size, and parity were 
proven to have independent influences on overall survival, and stage, tumor size and parity 
also independently influenced disease-specific survival in multivariate analysis. Many authors 
have come to the same conclusions as regards these traditional prognostic factors: age 
(Wolfson et al. 1994, Kokawa et al. 2006, Chan et al. 2008, Kapp et al. 2008, Nemani et al. 
2008, Gadducci 2011), stage (Wolfson et al. 1994, Chauveinc et al. 1999, Kokawa et al. 2006, 
Chan et al. 2008, Kapp et al. 2008, Nemani et al. 2008, Abeler et al. 2009, Gonzalez Bosquet 
et al. 2010) and tumor size (Wolfson et al. 1994, Nordal and Thoresen 1997, Wu et al. 2006, 
Abeler et al. 2009, D'Angelo et al. 2011). Tumor size is nowadays included in the new FIGO 
staging system (2009) of uterine LMS and ESS (Mutch 2009). 
Tumor grade has earlier been accepted as a prognostic factor of USs (Nordal et al. 1996, El 
Husseiny et al. 2002). In Study II, grade was statistically significantly associated with survival 
in univariate analysis but not in multivariate analysis. Its close association with stage could 
explain this. We still used the classification of LMS and ESS as low- and high-grade in Study 
II. Several different grading systems have been used and assessed in connection with USs 
(Pautier et al. 2000, Sleijfer et al. 2007), but no universally accepted grading system exists. In 
the WHO´s latest classification for the female genital organs, CS is a high-grade tumor and 
ESS a low-grade one (Tavassoli and Devilee, 2003). After reclassification there is now no 
benefit in assessing grade as a prognostic factor for CS and ESS. Although the grading of 
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LMS is still debated, a high tumor grade has been associated with worse prognosis of LMS 
patients (Gadducci 2011). 
The association between parity and prognosis in patients with USs is unclear, whereas 
nulliparity is associated with a worse prognosis in patients with endometrial cancer 
(Albrektsen et al. 2009a). However, in our series survival in all cases of US was negatively 
affected by increasing parity (up to three deliveries), both in univariate and multivariate 
analysis. Higher parity among CS patients has been associated both with better survival and 
higher risks of death and recurrence (Marth et al. 1997, Sagae et al. 2004), or no association at 
all has been detected (Nordal et al. 1997, Bodner-Adler et al. 2001).  
In a Norwegian study of 493 US patients, nulliparity was independently related to a worse 
prognosis only among patients with ESS (Albrektsen et al. 2009b). The authors have 
explained the positive effect of pregnancies on the prognosis of ESS by suggesting a possible 
suppressive effect of progesterone on very early disease, pregnancy-induced alteration in 
protein content of the uterus or an immunologic mechanism (Marth et al. 1997, Albrektsen et 
al. 2009b). Our results do not support these hypotheses. 
Our survival figures were somewhat better than those of our institution in 1958–1977 
(Kahanpaa et al. 1986) and nearly the same as in 1937–1964 (Nieminen and Soderlin 1974). 
Nieminen et al. found a 5-year survival rate as high as 54.7% (our 5-year overall survival rate 
was 51%), which could be explained by differences in the proportion of early stages in the 
study population. As expected, patients with ESS showed the best survival rate, even though 
the high-grade group (undifferentiated endometrial sarcomas) was included in our study. Our 
survival rates are comparable to or even better than those in similar studies (Table 7). Our 
high proportion of stage I diseases (54% of uterine sarcomas), radical primary surgery (lymph 
node status clarified in 52%) as well as the wide use of first-line therapies (78% of the 
patients: CT 41%, RT 51%) could to some degree explain our rates, although the role of LND 
and adjuvant therapies is very controversial (Amant et al. 2009a, Hensley 2011, Sampath, 
Gaffney 2011). Furthermore, nearly 70% of the cases with recurrent disease were treated by 
means of different treatment modalities. 
Some of the prognostic factors tested failed to reach statistical significance and this might be 
explained to some extent by the small sample size. We also observed clinically significant 
results in Study II. For example, the median survival time of LMS patients was 1.6 times 
longer than among CS patients and the median survival time of patients with US who had 
adjuvant RT was 2.4 times longer than that of patients without adjuvant RT. Furthermore, 
patients treated with adjuvant CT had a median survival time that was 8 months longer (72 
months versus 64 months).  
Our results confirm the status of the traditional prognostic factors of US (age, stage and tumor 
size) and relatively quite stable survival times in cases of these malignancies over many years. 
The biological behavior of uterine CS, LMS and ESS could be different that of endometrial 
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cancer and other gynecological cancers and the association of parity with different subgroups 
of US still remains an open question.    
 
Prognostic and clinical importance of p53, estrogen receptor-α  and progesterone 
receptor on uterine CS, LMS and ESS 
 
In Study III, we investigated uterine CS, LMS and ESS using a panel of ten IHC markers (Ki-
67, p53, CD10, CD44, desmin, SMA, AR, ER-α, PR and c-kit). Both the expression rate (all 
markers) and the association of the IHC markers (except for AR and c-kit) with survival were 
assessed.  
Mutation of the p53 tumor suppressor gene and overexpression of mutant p53 protein 
detected by IHC is a relatively frequent phenomenon in gynecological cancers (Berchuck et 
al. 1994). It has been related to the prognosis, for example, of ovarian malignancies (Ala-
Fossi et al. 1997, Lassus et al. 2003). We noticed that the expression rate of the mutant 
protein p53 in cases of CS and LMS was lower than in earlier reports (Nordal et al. 1998, 
Gokaslan et al. 2005, Chen and Yang 2008), and most of the ESS samples did not express 
p53, which is in line with the results of a recent study (D'Angelo et al. 2009). This finding is 
easily understandable because low-grade ESS usually has a low mitotic rate and on the other 
hand overexpression of mutated protein p53 is associated with cell proliferation (Tavassoli 
and Devilee 2003). In accordance with this, the high proportion of low-grade LMSs in our 
series could explain the low expression rate of p53 in LMS cases. On the other hand, high-
grade uterine CS is thought to be the most aggressive subtype of uterine malignancy (Amant 
et al. 2005, Vaidya et al. 2006) and this could be the reason for the high proportion of CS 
cases with negative p53. Aberrant p53 staining could be related to the aggressiveness of 
uterine CS, because both p53 overexpression and total negativity are thought to be strong and 
independent prognostic factors as regards overall survival in cases of serous ovarian 
carcinoma (Lassus et al. 2003, Lassus and Butzow 2007). In the present study, a strong 
survival benefit was associated only with p53-negative cases of LMS: the median survival 
time was 11 times longer among p53-negative patients than among p53-positive patients (123 
months vs 11 months, p = 0.011). Most earlier studies have shown the similar results, 
especially in cases of LMS  (Blom et al. 1998a, Anderson et al. 2006, Kim et al. 2006, 
D'Angelo et al. 2009). 
In the current study about 40% of cases with LMS and 50% of cases with ESS were positive 
for ER-α and PR and most cases of CS were ER-α- and PR-negative (77% and 74%). Both 
ER-α and PR expression in LMS cases were associated with better survival. Our results 
concerning expression rates of ER-α and PR in all US subgroups mostly concur with the 
results of earlier studies (Ansink et al. 1997, Leitao et al. 2004, Leitao et al. 2012). However, 
both lower and higher expression rates of ER-α have been published in connection with 
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patients with USs (Akhan et al. 2005, Kir et al. 2005, Ioffe et al. 2009), which could be 
related to differences in the study population and IHC methods. 
Many authors have agreed on the prognostic clinical significance of hormone receptor 
positivity among patients with LMS (Raspollini et al. 2003, Leitao et al. 2004, Akhan et al. 
2005, Ioffe et al. 2009, Leitao et al. 2012). The same issue has earlier been established in 
endometrial carcinoma and this phenomenon has in general been associated with the tumors 
derived from hormone receptor-positive tissue (Uharcek 2008). The significance of hormone 
receptor status has even been extended to concern all cases of US in a recent report (Ioffe et 
al. 2009). We can also speculate about clinically significant outcomes in cases of ESS and 
CS: all of the ESS patients with positive ER-α and PRA status were alive at the cut-off point 
for survival analysis in our study (these patients were alive at 107, 152, 177 and 184 months 
after ESS diagnosis), and the median survival time of CS patients with an ER-α-positive 
tumors was 102 months, compared with only 20 months among ER-α-negative patients. 
Expression of ER-α has been associated with a reduced risk of death, and, in contrast, 
overexpression of ER-β with advanced stage of disease among CS patients (Huang et al. 
2007, Huang et al. 2009). 
The hormone receptor status of malignancies may have an effect on prognosis and it can also 
be used in deciding on therapies. Hormone therapy, especially with progestins or aromatase 
inhibitors, has been gradually accepted as a standard of care in cases of ESS and it should be 
kept in mind in cases of ER-/PR-positive LMS (Amant et al. 2009a, Sjoquist et al. 2011). 
According to our results, IHC testing of ER-α and PR in cases of LMS and ESS can be 
recommended. On a larger scale, hormone therapy could be offered as one of the options for 
patients with recurrent, or even primary, hormone receptor-positive uterine sarcomas.  
 
Second primary cancer after first primary uterine sarcoma 
 
The present multicenter study showed that women with primary USs had a 26% increased risk 
of developing a new primary cancer compared with the general population. We observed 
excesses in cancers of the mouth and pharynx, colorectum, lung, breast, urinary bladder, 
kidney, thyroid gland, and soft tissue sarcomas. The only other study (to our knowledge) 
published on second primary cancers after first primary US showed comparable results 
(Curtis et al. 1985). 
The major etiologic groups of second malignancies are treatment-related, syndromic, and 
malignancies with shared etiologic factors (Travis et al. 2006), but strict surveillance after any 
first primary cancer should not be forgotten (Boice et al. 1985b). In this study, most of the 
kidney and thyroid cancers were detected within the first few years after diagnosis of US, 
when frequent monitoring after malignancy is usual and a surveillance effect or bias is most 
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likely an explanation for the elevated risks of these two cancer types after primary US. The 
increased incidence of colorectal and bladder cancers could be partly explained by the 
possible late effects of radiotherapy. Even though surgery is the most common treatment 
modality for any type of US, adjuvant radio- or chemotherapy is still used to different degrees 
(Gadducci et al. 2007, Hensley 2011, Sampath and Gaffney 2011). The probability of 
developing an independent second primary malignancy after radiotherapy increases with time 
(Welte et al. 2010), and both colorectal cancer and urinary bladder cancer have been linked to 
medical radiation (El Ghissassi et al. 2009). However, the elevated risk of bladder cancer 
could also be associated with chemotherapy. The risk of chemotherapy-induced second 
primary bladder cancers has been related to cyclophosphamide (Grosse et al. 2009), which 
has been used in the treatment of US during this study period (Muss et al. 1985, Benoit et al. 
2005).  
Smoking is a well-known risk factor for cancers of lung, mouth, pharynx, bladder and kidney 
(Dreyer et al. 1997). In the present study, we detected elevated risks after first primary US at 
all these cancer sites. However, cigarette smoking has been associated with a reduced risk of 
endometrial cancer, and earlier reports of second primary malignancies among patients with 
endometrial cancer have confirmed a negative and also a bidirectional association of 
smoking-related malignancies (Hemminki et al. 2003, Zhou et al. 2008, Brown et al. 2010). 
The mechanism behind the protective effect of smoking on endometrial cancer is that tobacco 
smokers tend to have less body fat and lower estrogen levels (Zhou et al. 2008). The only 
study on smoking and US showed odds ratios of 0.6 (95%CI 0.3–1.1) for LMS and 0.5 
(95%CI 0.1–1.2) for ESS among patients who had ever smoked (Schwartz et al. 1996). 
Although our results contrast with those reported by Schwartz and coworkers, we can still 
speculate that smoking might have an unknown carcinogenic effect on US.  
In our study, patients with US had an elevated risk of breast cancer. The relative risk was 
highest in women of 60 years of age and over at the time of diagnosis of US. Breast cancer 
has been linked to hormone treatment (Rossow et al. 2002), and some hormonal agents are 
thought to be associated with the risk of US (Schwartz et al. 1996, Wickerham et al. 2002, 
Arenas et al. 2006). In a recent study elevated risks of US were reported among 
postmenopausal women who used estradiol-progestin for five or more years (Jaakkola et al. 
2011). This is plausible, since estrogen, progesterone and androgen receptors are expressed in 
USs to different degrees (Ansink et al. 1997, Leitao et al. 2004, Akhan et al. 2005, Kir et al. 
2005, Ioffe et al. 2009, Leitao et. al 2012). The association between these malignancies could 
be explained by a shared hormonal etiology. Furthermore, obesity is one of the few known 
risk factors of US and also a risk factor of postmenopausal breast cancer, colorectal and renal 
cancers, all of which were increased among the US patients. Hence, shared risk factor 
etiology is another explanation for these findings.  
To the best of our knowledge, this is the largest US patient cohort ever collected for this kind 
of study. We were able to observe statistically significant associations between US and certain 
cancer types.  However, the rarity of USs and the lack of individual data on the patients 
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prevented us from assessing the proportion of different causes for the excess risks of second 
primary malignancies. The results of the present study emphasize the need for long-term 
caution as regards new malignancies among women with US. 
 
 
Implications for future research 
 
Our results emphasize the rareness of USs and the lack of information on possible etiological 
and risk factors and treatment modalities. Future research should be focused on multinational 
(for example Nordic) cooperation linking national registries of birth (association with parity), 
medical reimbursement (hormone replacement therapy, use of levonorgestrel-releasing IUDs) 
and hospital discharge (anamnestic factors: body mass index, smoking habits etc. and earlier 
diseases) to databases such as NORDCAN and NOCCA. More efforts should be made to 
conduct prospective trials to assess different therapy strategies in cases of US. Since it is 
difficult to find enough material for such studies in gynecologic oncology centers in Finland, 
more extensive cooperation with international clinical trial organizations such as NSGO, 
AGO, ENGOT etc. would be needed. Because of the variable biological behavior of USs, 
subgroup analysis has an essential role in large, multinational studies. The aim could be 
assessment of different therapy strategies in connection with US – LMS, ESS, adenosarcoma 
and UES. It would be particularly interesting to study progestins, mifepristone (Koivisto-
Korander et al. 2007), and aromatase inhibitors in cases of recurrence and in adjuvant settings 
alone or with chemotherapy among patients with LMS and ESS. New biologic agents such as 
tyrosine kinase inhibitors should also be evaluated further in the treatment of USs. 
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CONCLUSIONS 
!
On the basis of the present work the following conclusions can be drawn 
1. During the study period (1978–2007), the incidences of LMS and ESS showed slight 
differences between the Nordic countries concerned and only minor changes in incidence over 
time. In our study the age-specific incidences of LMS and ESS increased up to the age groups 
around menopause (45–59 years), but decreased after the age of 60 in cases of LMS. There 
were some differences in uterine sarcoma incidences related to occupational factors (leather 
work) which merit further investigation. 
 
2. The disease-specific and overall survival rates were slightly better than in nearly all 
previous similar studies of uterine sarcomas. Stage, age, tumor size and parity were found to 
be the most important prognostic factors as regards survival. The association between parity 
and USs should be further studied.   
3. The expression of p53, ER-α and PR in uterine LMS may give prognostic information 
concerning the behavior of the disease and IHC testing for ER-α and PR in cases of LMS is 
recommended. Patients with ESS might also benefit from testing for hormone receptor 
expression. Patients with LMS and ESS should also have the option of hormone therapy in 
adjuvant and recurrent settings. 
4. Uterine sarcoma survivors had a 26% increased risk of developing a second primary 
cancer, such as cancers of the mouth and pharynx, colorectum, lung, breast, urinary bladder, 
kidney, thyroid gland, and soft tissue sarcomas. Colorectal and urinary bladder cancer may be 
related to the use of pelvic radiotherapy or chemotherapy (urinary bladder only). The other 
associations are more difficult to explain.  
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